Intraluminal method and apparatus for ablating nerve tissue

Information

  • Patent Grant
  • 9707034
  • Patent Number
    9,707,034
  • Date Filed
    Wednesday, May 23, 2012
    12 years ago
  • Date Issued
    Tuesday, July 18, 2017
    7 years ago
Abstract
Methods and apparatus for treating gastroesophageal reflex and other luminal conditions provide for delivering acoustic energy to a body lumen to remodel tissue surrounding the body lumen. In the case of treating GERD, a catheter carrying an ultrasonic or other vibrational transducer is introduced to the lower esophageal sphincter, and acoustic energy is delivered to the sphincter in order to tighten or bulk the sphincter such that reflex is reduced.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


In a general sense, the invention is directed to systems and methods for treating interior tissue regions of the body. More specifically, the invention is directed to systems and methods for treating dysfunction in body sphincters and adjoining tissue, e.g., in and around the lower esophageal sphincter and cardia of the stomach.


2. Description of the Background Art


The gastrointestinal (GI) tract extends from the mouth to the anus, and includes the esophagus, stomach, small and large intestines, and rectum. Along the way, ring-like muscle fibers called sphincters control the passage of food from one specialized portion of the GI tract to another. The GI tract is lined with a mucosal layer about 1-2 mm thick that absorbs and secretes substances involved in the digestion of food and protects the body's own tissue from self-digestion. The esophagus is a muscular tube that extends from the pharynx through the esophageal hiatus of the diaphragm to the stomach. Peristalsis of the esophagus propels food toward the stomach as well as clears any refluxed contents of the stomach.


The junction of the esophagus with the stomach is controlled by the lower esophageal sphincter (LES), a thickened circular ring of smooth esophageal muscle. The LES straddles the squamocolumnar junction, or z-line--a transition in esophageal tissue structure that can be identified endoscopically. At rest, the LES maintains a high-pressure zone between 10 and 30 mm Hg above intragastric pressures. The LES relaxes before the esophagus contracts, and allows food to pass through to the stomach. After food passes into the stomach, the LES constricts to prevent the contents from regurgitating into the esophagus. The resting tone of the LES is maintained by muscular and nerve mechanisms, as well as different reflex mechanisms, physiologic alterations, and ingested substances. Transient LES relaxations may manifest independently of swallowing. This relaxation is often associated with transient gastroesophageal reflux in normal people. Muscular contractions of the diaphragm around the esophageal hiatus during breathing serve as a diaphragmatic sphincter that offers secondary augmentation of lower esophageal sphincter pressure to prevent reflux.


The stomach stores, dissolves, and partially digests the contents of a meal, then delivers this partially digested food across the pyloric sphincter into the duodenum of the small intestine in amounts optimal for maximal digestion and absorption. Feelings of satiety are influenced by the vagally modulated muscle tone of the stomach and duodenum as well as through the reception and production of biochemicals (e.g., hormones) therein, particularly the gastric antrum.


Finally, after passage of undigested food into the large intestine, it is passed out of the body through the anal sphincter. Fluids unused by the body are passed from the kidneys into the bladder, where a urinary sphincter controls their release.


A variety of diseases and ailments arise from the dysfunction of a sphincter. Dysfunction of the lower esophageal sphincter, typically manifest through transient, relaxations, leads to reflux of stomach acids into the esophagus. One of the primary causes of the sphincter relaxations is believed to be aberrant vagally-mediated nerve impulses to the LES and cardia (upper part of the stomach). This condition, called Gastroesophageal Reflux Disease (GERD), creates discomfort such as heartburn and with time can begin to erode the lining of the esophagus—a condition that can progress to esophagitis and a pre-cancerous condition known as Barrett's Epithelium. Complications of the disease can progress to difficulty and pain in swallowing, stricture, perforation and bleeding, anemia, and weight loss. Dysfunction of the diaphragmatic sphincter, such as that caused by a hiatal hernia, can compound the problem of LES relaxations. It has been estimated that approximately 7% of the adult population suffers from GERD on a daily basis. The incidence of GERD increases markedly after the age of 40, and it is not uncommon for patients experiencing symptoms to wait years before seeking medical treatment.


Treatment of GERD includes drug therapy to reduce or block stomach acid secretions, and/or increase LES pressure and peristaltic motility of the esophagus. Most patients respond to drug therapy, but it is palliative in that it does not cure the underlying cause of sphincter dysfunction, and thus requires lifelong dependence. Invasive abdominal surgical intervention has been shown to be successful in improving sphincter competence. One procedure, called Nissen fundoplication, entails invasive, open abdominal surgery. The surgeon wraps the gastric fundis about the lower esophagus, to, in effect, create a new “valve.” Less invasive laparoscopic techniques have also been successful in emulating the Nissen fundoplication. As with other highly invasive procedures, antireflux surgery is associated with the risk of complications such as bleeding and perforation. In addition, a significant proportion of individuals undergoing laparascopic fundoplication report difficulty swallowing (dysphagia), inability to vomit or belch, and abdominal distention.


In response to the surgical risks and drug dependency of patients with GERD, new trans-oral endoscopic technologies are being evaluated to improve or cure the disease. One approach is the endoscopic creation and suturing of folds, or plications, in the esophageal or gastric tissue in proximity to the LES, as described by Swain, et al, [Abstract], Gastrointestinal Endoscopy, 1994; 40:AB35. Another approach, as described in U.S. Pat. No. 6,238,335, is the delivery of biopolymer bulking agents into the muscle wall of the esophagus. U.S. Pat. No. 6,112,123 describes RF energy delivery to the esophageal wall via a conductive medium. Also, as described in U.S. Pat. No. 6,056,744, RF energy has been delivered to the esophageal wall via discrete penetrating needles. The result is shrinkage of the tissue and interruption of vagal afferent pathways some believe to play a role in the transient relaxations of the LES.


The above endoscopic techniques all require the penetration of the esophageal wall with a needle-like device, which entails the additional risks of perforation or bleeding at the puncture sites. Special care and training by the physician is required to avoid patient injury. Use of the plication technique requires many operational steps and over time sutures have been reported to come loose and/or the tissue folds have diminished or disappeared. Control of the amount and location of bulking agent delivery remains an art form, and in some cases the agent has migrated from its original location. RF delivery with needles requires careful monitoring of impedance and temperature in the tissue to prevent coagulation around the needle and associated rapid increases in temperature. Lesion size is also limited by the needle size. Limitations of the design require additional steps of rotating the device to achieve additional lesions. Physicians have to be careful not to move the device during each of the multiple one-minute energy deliveries to ensure the needles do not tear the tissue.


Dysfunction of the anal sphincter leads to fecal incontinence, the loss of voluntary control of the sphincter to retain stool in the rectum. Fecal incontinence is frequently a result of childbearing injuries or prior anorectal surgery. In most patients, fecal incontinence is initially treated with conservative measures, such as biofeedback training, alteration of the stool consistency, and the use of colonic enemas or suppositories. Biofeedback is successful in approximately two-thirds of patients who retain some degree of rectal sensation and functioning of the external anal sphincter. However, multiple sessions are often necessary, and patients need to be highly motivated. Electronic home biofeedback systems are available and may be helpful as adjuvant therapy. Several surgical approaches to fecal incontinence have been tried, with varying success, when conservative management has failed. These treatments include sphincter repair, gracilis or gluteus muscle transposition to reconstruct an artificial sphincter, and sacral nerve root stimulation. The approach that is used depends on the cause of the incontinence and the expertise of the surgeon. Surgical interventions suffer from the same disadvantages discussed above with respect to GERD. An RF needle ablation device, similar in design to that described above for treatment of GERD, has been described in WO/01/80723. Potential device complications and use limitations are similar to those described for GERD.


Dysfunction of the urinary sphincter leads to urinary incontinence, the loss of voluntary control of the sphincter to retain urine in the bladder. In women this is usually manifest as stress urinary incontinence, where urine is leaked during coughing, sneezing, laughing, or exercising. It occurs when muscles and tissues in the pelvic floor are stretched and weakened during normal life events such as childbirth, chronic straining, obesity, and menopause. In men, urinary incontinence is usually a result of pressure of an enlarged prostate against the bladder.


U.S. Pat. No. 6,073,052 describes a method of sphincter treatment using a microwave antennae and specific time and temperature ranges, and U.S. Pat. No. 6,321,121 a method of GERD treatment using a non-specific energy source, with limited enabling specifications. The use of ultrasound energy for circumferential heating of the pulmonary vein to create electrical conduction block has been described in U.S. Pat. Nos. 6,012,457 and 6,024,740. The use of ultrasound for tumor treatments has been described in U.S. Pat. No. 5,620,479.


In view of the foregoing, and notwithstanding the various efforts exemplified in the prior art, there remains a need for a more simple, rapid, minimally invasive approach to treating sphincters that minimizes risk to the patient.


SUMMARY OF THE INVENTION

The present invention seeks to heat sphincter tissues using ultrasound energy. The preferred method is to use ultrasound energy to heat tissue and thus create necrotic regions (lesions) in the tissue. The lesions tighten the tissue by shrinking it (through dessication, protein denaturation, and disruption of collagen bonds), and/or bulking it (with new collagen formation). The lesions also prevent or delay opening of the sphincter by reducing the compliance of the tissue in either or both the radial and longitudinal directions as the sphincter is forced to expand and shorten when the internal pressure increases. The lesions also interrupt nerve pathways responsible for sphincter relaxations. In general, during the heating process, the invention employs means to minimize heat damage to the mucosal layer of the sphincter. However, in the case of Barrett's Esophagus, selective heating of the intestinal metaplasia on the luminal surface of the esophagus is preferred. Ultrasound may also be used (continuously or in pulsed mode) to create shock waves that cause mechanical disruption through cavitation that create the desired tissue effects. While this invention relates broadly to many tissue sphincters in the body, the focus of the disclosure will be on the treatment of a dysfunctional lower esophageal sphincter (LES) responsible for GERD.


The key advantage of an ultrasound ablation system over others is that a uniform annulus of tissue can be heated simultaneously. Alternatively, the transducers can be designed so that only user-defined precise regions of the circumference are heated. Ultrasound also penetrates tissue deeper than RF or simple thermal conduction, and therefore can be delivered with a more uniform temperature profile. Thus lesions can be created at deeper locations than could be safely achieved with RF needles puncturing the tissue. Similarly, the deeper heating and uniform temperature profile also allow for an improved ability to create a cooling gradient at the surface. Relatively low power can be delivered over relatively long durations to maximize tissue penetration but minimize surface heating. If only surface heating is desired, as in the case of Barrett's Esophagus, the acoustic energy can be focused at or just before the tissue surface. Another means to selectively heat the tissue surface is to place a material against the tissue, between the tissue and the transducer, that selectively absorbs acoustic energy and preferentially heats at the tissue interface. A device using ultrasound for ablation may also be configured to allow diagnostic imaging of the tissue to determine the proper location for therapy and to monitor the lesion formation process.


In a first specific aspect of the present invention, methods for remodeling luminal tissue comprise positioning a vibrational transducer at a target site in a body lumen of a patient. The vibrational transducer is energized to produce acoustic energy under conditions selected to induce tissue remodeling in at least a portion of the tissue circumferentially surrounding the body lumen. In particular, the tissue remodeling may be directed at or near the luminal surface, but will more usually be directed at a location at a depth beneath the luminal surface, typically from 1 mm to 10 mm, more usually from 2 mm to 6 mm. In the case of Barrett's Esophagus, the first 1 to 3 mm of tissue depth is to be remodeled. In the most preferred cases, the tissue remodeling will be performed in a generally uniform matter on a ring or region of tissue circumferentially surrounding the body lumen, as described in more detail below.


The acoustic energy will typically be ultrasonic energy produced by electrically exciting an ultrasonic transducer which may optionally be coupled to an ultrasonic horn, resonant structure, or other additional mechanical structure which can focus or enhance the vibrational acoustic energy. In an exemplary case, the transducer is a phased array transducer capable of selectively focusing and/or scanning energy circumferentially around the body lumen.


The acoustic energy is produced under conditions which may have one or more of a variety of biological effects. In many instances, the acoustic energy will be produced under conditions which cause shrinkage of the tissue, optionally by heating the tissue and inducing shrinkage of the collagen. Alternatively or additionally, the acoustic energy may be produced under conditions which induce collagen formation in order to bulk or increase the mass of tissue present. Such collagen formation may in some cases, at least, result from cavitation or other injury-producing application of the vibrational energy. Thus, under some conditions, the vibrational energy will be produced under conditions which cause cavitation within the tissues. Additionally, the acoustic energy may be produced under conditions which interrupt nerve pathways within the tissue, such as the vagal nerves as described in more detail hereinafter.


Preferred ultrasonic transducers may be energized to produce unfocused acoustic energy from the transducer surface in the range from 10 W/cm.sup.2 to 100 W/cm.sup.2, usually from 30 W/cm.sup.2 to 70 W/cm.sup.2. The transducer will usually be energized at a duty cycle in the range from 10% to 100%, more usually from 70% to 100%. Focused ultrasound may have much higher energy densities, but will typically use shorter exposure times and/or duty cycles. In the case of heating the tissue, the transducer will usually be energized under conditions which cause a temperature rise in the tissue to a tissue temperature in the range from 55.degree. C. to 95.degree. C., usually from 60.degree. C. to 80.degree. C. In such instances, it will usually be desirable to cool the luminal surface, which is a mucosal surface in the case of the esophagus which may treated by the present invention, in order to reduce the risk of injury.


Usually, the vibrational transducer will be introduced to the body lumen using a catheter which carries the transducer. In certain specific embodiments, the transducer will be carried within an inflatable balloon on the catheter, and the balloon when inflated will at least partly engage the luminal wall in order to locate the transducer at a pre-determined position relative to the luminal target site. In a particular instance, the transducer is disposed within the inflatable balloon, and the balloon is inflated with an acoustically transmissive material so that the balloon will both center the transducer and enhance transmission of acoustic energy to the tissue. In an alternative embodiment, the transducer may be located between a pair of axially spaced-apart balloons. In such instances, when the balloons are inflated, the transducer is centered within the lumen. Usually, an acoustically transmissive medium is then introduced between the inflated balloons to enhance transmission of the acoustic energy to the tissue. In any of these instances, the methods of the present invention optionally comprise moving the transducer relative to the balloons, typically in an axially direction, in order to focus or scan the acoustic energy at different locations on the luminal tissue surface.


In specific embodiments, the acoustically transmissive medium may be cooled in order to enhance cooling of the luminal tissue surface. Additionally, the methods may further comprise monitoring temperature of the luminal tissue surface and/or at a point beneath the luminal tissue surface.


In other specific examples, methods of the present invention further comprise focusing acoustic energy beneath the luminal tissue surface. Or in the case of Barrett's Esophagus, acoustic energy is focused at or just before the luminal tissue surface. In such instances, focusing may be achieved using a phased array (by selectively energizing particular elements of the array) and the tissue may be treated at various locations and various depths.


The methods as described above are particularly preferred for treating patients suffering from gastroesophageal reflex disease (GERD) where the acoustic energy remodels the tissue surrounding a lower esophageal sphincter (LES). In other instances, the methods of the present invention may be used to treat patients suffering hiatal hernias, where the acoustic energy is directed at tissue surrounding a diaphragmatic sphincter above the LES, to treat the anal sphincter for incontinent patients, to remodel tissues of the bladder neck and surrounding endopelvic fascia for urinary stress incontinence, etc. Further, the methods of the present invention can be used to induce feelings of satiety in obese patients, where acoustic energy is delivered to regions of the stomach and small intestine to interrupt or modify vagal mediation of muscle tone, or to block or modify the reception and production of biochemicals that affect satiety. The acoustic energy may also be used to selectively necrose or shrink tissue in the pylorus to delay gastric emptying and prolong the sensation of fullness. Acoustic energy may also be used to render regions of tissue unable to absorb food.


The methods of the present invention may further comprise introducing a cannula to the target site, expanding a balloon on the cannula at the target site with an acoustically transmissive medium, and selectively directing the vibrational transducer within the balloon to remodel targeted tissue. The balloon can provide a relatively large working space and optionally can seal an opening to the body lumen, such as to the esophagus. Optionally, a viewing scope or other viewing means can be introduced into the balloon on the cannula to allow visualization of the tissue being treated. In such cases, the acoustically transmissive medium should also be transparent. Within the inflated balloon, the transducer on the catheter may be manipulated in a variety of ways, including deflecting, rotating, everting, and the like, in order to direct the vibrational energy precisely where desired. Alternatively or additionally, phased array and other circumferential array transducers may be axially translated to otherwise selectively positioned to achieve a desired therapy. When used at the end of the esophagus or at another opening to a body lumen, the balloon on the cannula may be expanded to cover the entire opening or alternatively may be expanded over a location adjacent to the opening.


In other embodiments, directing the transducer may comprise selectively pivoting at least one transducer from a fixed location on the catheter or otherwise within the balloon, optionally comprising deflecting at least two catheters from spaced-apart locations. In such cases, the two transducers may be used together in order to focus energy at particular location(s) within the target tissue.


In yet another aspect of the present invention, positioning the transducer may comprise capturing luminal tissue between opposed elements on the catheter where the transducer is disposed on at least one of the elements. The energy may then be directed from the transducer into the captured tissue. Capturing may comprise clamping the tissue between moveable elements and/or applying a vacuum to the tissue to draw tissue between the opposed elements.


The present invention still further comprises apparatus for remodeling the lower esophageal sphincter. Such apparatus comprise a catheter or probe adapted to be esophageally introduced to the lower esophageal sphincter and a vibrational transducer on the catheter. The transducer is adapted to deliver acoustic energy to the tissue of the LES in order to lessen gastroesophageal reflux. Apparatus for treating other sphincters may also be provided for certain sphincters such as the anal sphincter. The apparatus may comprise a more rigid probe instead of a highly flexible catheter.


Specific apparatus constructions include providing an inflatable balloon on the catheter, where the balloon is adapted when inflated to position the catheter within the LES so that the transducer can deliver energy to the LES. The transducer is usually positioned coaxially within the balloon, and means may be provided for inflating the balloon with an acoustically transmissive medium.


Alternatively, the transducer may be positioned between a pair of axially-spaced-apart balloons, where the apparatus will typically further comprise means for delivering an acoustically transmissive medium between the balloons. In all instances, the apparatus may further comprise means for cooling the acoustically transmissive medium, and means for axially translating the transducer relative to the catheter. In certain specific examples, the transducer comprises a phased array transducer.


The present invention may further comprise systems including apparatus as set forth above in combination with a cannula having a channel for receiving and deploying the catheter of the apparatus. Usually, the systems will further include a viewing scope or other imaging component which is either part of the cannula or introducable through the cannula.


In preferred embodiments, the cannula further comprises an inflatable balloon formed over a distal end thereof, where the catheter is extendable from the cannula into the balloon when the balloon is inflated. In such embodiments, the vibrational transducer on the catheter is preferably deflectable, rotatable, and/or evertable within the balloon when inflated to allow a high degree of selective positioning of the transducer. Alternatively, the vibrational transducer may comprise a circumferential array which is axially translatable or otherwise positionable on the catheter when the balloon is inflated. Still further optionally, the transducer(s) may comprise pivotally mounted transducers on the catheter to permit separate or focused positioning of the transducers. Still further alternatively, the transducer(s) may be mounted on a pair of spaced-apart elements on the catheter, where the elements are configured to receive target tissue therebetween. Usually, the elements will be movable to clamp tissue therebetween and/or a vacuum source will be provided on the catheter to selectively draw tissue into the space between the spaced-apart elements.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an illustration of the tissue structures comprising the esophagus and stomach.



FIG. 2 is an Ultrasound Ablation System for GERD Treatment.



FIG. 3 is an Ultrasound Ablation Catheter.



FIG. 4a illustrates the diagnostic endoscopic procedure used to identify the target treatment area.



FIG. 4b illustrates the delivery of the tissue treatment apparatus.



FIG. 5 illustrates the positioning of the ultrasound transducer and balloon at the region of the lower esophageal sphincter.



FIG. 6 illustrates the positioning of the “rear-directed” ultrasound transducer and balloon distal to the lower esophageal sphincter for delivering energy to the inferior aspect of the lower esophageal sphincter and the cardia.



FIG. 7 is a preferred pattern of completely circumferential lesions.



FIG. 8 is a preferred pattern of groups of discrete lesions formed in circumferential groups.



FIG. 9 is a cylindrical PZT material.



FIG. 10 is an annular array of flat panel transducers and the acoustic output from the array.



FIG. 11 is isolated active sectors of a transducer formed by isolating the plated regions.



FIG. 12 is a selective plating linked with continuous plating ring.



FIG. 13 is a cylindrical transducer with non-resonant channels.



FIG. 14 is a cylindrical transducer with an eccentric core.



FIG. 15 is a cylindrical transducer with curved cross-section and resulting focal region of acoustic energy.



FIG. 16 is an illustration of acoustic output from conical transducers.



FIG. 17 is a longitudinal array of cylindrical transducers.



FIG. 18 is a transducer mounting configuration using metal mounts.



FIG. 19 shows transducer geometry variations used to enhance mounting integrity.



FIG. 20 is transducer plating variations used to enhance mounting integrity.



FIG. 21 shows cooling flow through the catheter center lumen, exiting the tip.



FIG. 22 shows cooling flow recirculating within the catheter central lumen.



FIG. 23 shows cooling flow circulating within the balloon.



FIG. 24 shows cooling flow circulating within a lumen/balloon covering the transducer.



FIG. 25 shows cooling flow circulating between an inner and an outer balloon.



FIG. 26 is an ultrasound ablation element bounded by tandem occluding members.



FIG. 27 shows sector occlusion for targeted ablation and cooling.



FIG. 28 shows thermocouples incorporated into proximally slideable splines positioned over the outside of the balloon.



FIG. 29 shows thermocouples incorporated into splines fixed to the shaft but tethered to the distal end with an elastic member.



FIG. 30 shows thermocouples attached to the inside of the balloon, aligned with the ultrasound transducer.



FIG. 31 shows thermocouples positioned on the outside of the balloon, aligned with the ultrasound transducer, and routed across the wall and through the inside of the balloon.



FIGS. 32a-32c show the use of a slit in the elastic encapsulation of a thermocouple bonded to the outside of an elastic balloon that allows the thermocouple to become exposed during balloon inflation.



FIG. 33 shows thermocouples mounted on splines between two occluding balloons and aligned with the transducer.



FIG. 34a is an Ultrasound Ablation System for GERD Treatment that includes an ablation catheter with a tip controllable from a member attached to the distal tip.



FIG. 34b is an Ultrasound Ablation System for GERD Treatment that includes an ablation catheter with a tip optionally controlled via an internal tensioning mechanism.



FIG. 35 illustrates the deployment of an overtube with balloon over an endoscope.



FIG. 36 illustrates retraction of the endoscope within the balloon of the overtube.



FIG. 37 illustrates inflation of the overtube balloon at the region of the Lower Esophageal Sphincter (LES).



FIG. 38a illustrates advancement of the ablation catheter out of the endoscope.



FIG. 38b illustrates manipulation of the tip of the ablation catheter in order to direct the energy in a particular direction.



FIG. 39 illustrates lesion formation from above the LES using the preferred system.



FIG. 40 illustrates lesion formation from below the LES using the preferred system.



FIG. 41 illustrates lesion formation during the forward delivery of ultrasound from a transducer mounted on the tip of the catheter.



FIG. 42 illustrates lesion formation using the preferred catheter with one external pullwire routed through a second open channel of the endoscope. A smaller, simper overtube balloon is also used.



FIG. 43 illustrates lesion formation using a catheter advanced through an endoscope channel. No overtube is used; instead, a balloon is mounted on the catheter tip which inflates outward from the tip of the shaft.



FIG. 44 illustrates lesion formation using a deflectable or preshaped catheter advanced out on an endoscope channel. The overtube has a member extending distally from the distal opening of the overtube. The balloon is mounted at its distal end to the distal end of the member. The member has one or more lumens for fluid delivery and guide wire use.



FIG. 45 illustrates the deployment of an overtube having a doughnut shaped balloon.



FIG. 46 illustrates the lesion formation from an ultrasound ablation catheter positioned inside the doughnut shaped balloon of the overtube.



FIG. 47 illustrates lesion formation from a catheter having either or both distal and proximal ablation elements mounted within a peanut shaped balloon.



FIGS. 48a-48d illustrate alternative means for changing the orientation of the ultrasound transducer.



FIG. 49a illustrates lesion formation from an ablation catheter while sealing the distal LES orifice with a balloon catheter.



FIG. 49b illustrates lesion formation from an ablation catheter while sealing the distal LES orifice with a balloon catheter and sealing the esophagus proximal to the LES with a balloon on an overtube.



FIG. 49c illustrates the use of a stasis valve between the overtube and endoscope to prevent fluid from flowing out the lumen between the two devices.



FIGS. 49d and 49e illustrate different embodiments of the stasis valve mounted on the tip of the overtube.



FIG. 50 illustrates lesion formation from an ablation catheter routed through 2 available channels in the endoscope while sealing the distal LES orifice with a balloon catheter.



FIG. 51 illustrates lesion formation from an ablation catheter having a membrane surrounding the transducer while a balloon attached to the opposite side of the shaft forcing the transducer against the tissue.



FIGS. 52a and 52b illustrate the use of an ablation device that sucks tissue in the region of the LES into a chamber where energy delivered into captured tissue.



FIGS. 53a and 53b illustrate the use of mechanical swivel grips to draw tissue into and hold within an ablation chamber.



FIG. 53c illustrates the use of wire to press tissue into and hold within an ablation chamber.



FIG. 53d illustrates the use of inflatable doughnuts to press tissue into and hold within an ablation chamber.





DETAILED DESCRIPTION OF THE INVENTION

This Specification discloses various catheter-based systems and methods for treating dysfunction of sphincters and adjoining tissue regions in the body. The systems and methods are particularly well suited for treating these dysfunctions in the upper gastrointestinal tract, e.g., in the lower esophageal sphincter (LES) and adjacent cardia of the stomach. For this reason, the systems and methods will be described in this context.


Still, it should be appreciated that the disclosed systems and methods are applicable for use in treating other dysfunctions elsewhere in the body, which are not necessarily sphincter-related. For example, the various aspects of the invention have application in procedures requiring treatment of hemorrhoids, or incontinence, or restoring compliance to or otherwise tightening interior tissue or muscle regions. The systems and methods that embody features of the invention are also adaptable for use with systems and surgical techniques that are not necessarily catheter-based.


In general, this disclosure relates to the ability of the ultrasound to heat the tissue in order to cause it to acutely shrink and tighten. It should also be noted that another physiologic means by which the tissue may move inward after heating is through the stimulation of new collagen growth during the healing phase. Besides swelling the wall, it may also serve to strengthen the wall. Further, by necrosing viable tissue, vagal afferent pathways responsible for transient relaxations of the LES are reduced or eliminated, leading to improved tonic contraction of the LES.


For the purposes of stimulating collagen growth, it may be sufficient to deliver shock waves to the tissue such that the tissue matrix is mechanically disrupted (i.e, via cavitation), but not necessarily heated. This is another means by which ultrasound could be a more beneficial energy modality than others. The ultrasound could be delivered in high-energy MHz pulses or through lower energy kHz or “lithotriptic” levels.


As FIG. 1 shows, the esophagus 10 is an approximately 25 cm long muscular tube that transports food from the mouth to the stomach 12 using peristaltic contractions. Mucous is secreted from the walls of the esophagus to lubricate the inner surface and allow food to pass more easily.


The junction of the esophagus 10 with the stomach 12 is controlled by the lower esophageal sphincter (LES) 18, a thickened circular ring of smooth esophageal muscle. The LES straddles the squamocolumnar junction, or z-line 14—a transition in esophageal tissue structure that can be identified endoscopically. An upper region of the stomach 12 that surrounds the LES 18 is referred to as the cardia 20. After food passes into the stomach 12, the LES 18 constricts to prevent the contents from regurgitating into the esophagus 10. Muscular contractions of the diaphragm 16 around the esophageal hiatus 17 during breathing serve as a diaphragmatic sphincter that offers secondary augmentation of lower esophageal sphincter pressure to prevent reflux.


The LES 18 relaxes before the esophagus 10 contracts, and allows food to pass through to the stomach 12. After food passes into the stomach 12, the LES 18 constricts to prevent the contents from regurgitating into the esophagus 10. The resting tone of the LES 18 is maintained by muscular and nerve mechanisms, as well as different reflex mechanisms, physiologic alterations, and ingested substances. Transient LES relaxations may manifest independently of swallowing. This relaxation is often associated with transient gastroesophageal reflux in normal people.


Dysfunction of the LES 18, typically manifest through transient relaxations, leads to reflux of stomach acids into the esophagus 10. One of the primary causes of the sphincter relaxations is believed to be aberrant vagally-mediated nerve impulses to the LES 18 and cardia 20. This condition, called Gastroesophageal Reflux Disease (GERD), creates discomfort such as heartburn and other debilitating symptoms. Dysfunction of the diaphragmatic sphincter (at the esophageal hiatus 17), such as that caused by a hiatal hernia, can compound the problem of LES relaxations.


It should be noted that the views of the esophagus and stomach shown in FIG. 1 and elsewhere in the drawings are not intended to be strictly accurate in an anatomic sense. The drawings show the esophagus and stomach in somewhat diagrammatic form to demonstrate the features of the invention.


As shown in FIG. 2, the present invention relates to an ablation system 30 consisting of an ablation device 32 with an acoustic energy delivery element (ultrasound transducer) 34 mounted on the distal end of the catheter. The device is delivered transorally to the region of the LES 18. The system 30 consists of the following key components:


1. A catheter shaft 36 with proximal hub 38 containing fluid ports 40, electrical connectors 42, and optional central guidewire lumen port 44.


2. An ultrasound transducer 34 that produces acoustic energy 35 at the distal end of the catheter shaft 36


3. An expandable balloon 46 operated with a syringe 48 used to create a fluid chamber 50 that couples the acoustic energy 35 to the tissue 60


4. Temperature sensor(s) 52 in the zone of energy delivery


5. An energy generator 70 and connector cable(s) 72 for driving the transducer and displaying temperature values


6. A fluid pump 80 delivering cooling fluid 82.


As shown in FIG. 3, the preferred embodiment of the ablation device consists of an ultrasound transducer 34 mounted within the balloon 46 near the distal end of an elongated catheter shaft 36. A proximal hub, or handle, 38 allows connections to the generator 70, fluid pump 80, and balloon inflation syringe 48. In other embodiments (not shown) the hub/handle 38 may provide a port for a guidewire and an actuator for deflection or spline deployment. The distal tip 39 is made of a soft, optionally preshaped, material such as low durometer silicone or urethane to prevent tissue trauma. The ultrasound transducer 34 is preferably made of a cylindrical ceramic PZT material, but could be made of other materials and geometric arrangements as are discussed in more detail below. Depending on performance needs, the balloon 46 may consist of a compliant material such as silicone or urethane, or a more non-compliant material such as nylon or PET, or any other material having a compliance range between the two. Temperature sensors 52 are aligned with the beam of acoustic energy 35 where it contacts the tissue. Various configurations of temperature monitoring are discussed in more detail below. The catheter is connected to an energy generator 70 that drives the transducer at a specified frequency. The optimal frequency is dependent on the transducer 34 used and is typically in the range of 7-10 MHz, but could be 1-40 MHz. The frequency may be manually entered by the user or automatically set by the generator 70 when the catheter is connected, based on detection algorithms in the generator. The front panel of the generator 70 displays power levels, delivery duration, and temperatures from the catheter. A means of detecting and displaying balloon inflation volume and/or pressure, and cooling flow rate/pressure may also be incorporated into the generator. Prior to ablation, the balloon 46 is inflated with a fluid such as saline or water, or an acoustic coupling gel, until it contacts the esophagus over a length exceeding the transducer length. Cooling fluid 82 is used to minimize heat buildup in the transducer and keep the mucosal surface temperatures in a safe range. In the preferred embodiment shown, cooling fluid 82 is circulated in through the balloon inflation lumen 51 and out through the central lumen 53 using a fluid pump 80. As described later, the circulation fluid may be routed through lumens different than the balloon lumen, requiring a separate balloon inflation port 39. Also, it may be advantageous to irrigate the outer proximal and/or distal end of the balloon to cool it and to ensure the expulsion or air on the outer edges of the balloon that could interfere with the coupling of the ultrasound into the tissue. The path of this irrigating fluid could be from a lumen in the catheter and out through ports proximal and/or distal to the balloon, or from the inner lumen of a sheath placed over the outside of or alongside the catheter shaft.


In other embodiments (not shown) of the catheter, the central lumen 53 could allow passage of a guidewire (i.e., 0.035″) from a proximal port 44 out the distal tip 39 for atraumatic placement into the body. Alternatively, a monorail guidewire configuration could be used, where the catheter 30 rides on the wire just on the tip section 39 distal to the transducer 34. A central lumen with open tip configuration would also allow passage of an endoscope for visualization during the procedure. The catheter could also be fitted with a pull wire connected to a proximal handle to allow deflection to aid in placement through the mouth and down the esophagus. This could also allow deflection of an endoscope in the central lumen. The balloon may also be designed with a textured surface (i.e., adhesive bulbs or ribs) to prevent movement in the inflated state. Finally, the catheter shaft or balloon or both could be fitted with electrodes that allow pacing and electrical signal recording within the esophagus.


The above ablation device 32 is configured as an elongated catheter. Of course, depending on the sphincter being treated, the ablation device may be configured as a probe, or a surgically delivered instrument.


In use (see FIGS. 4a, 4b, 5 and 6), the patient lies awake but sedated in a reclined or semi-reclined position. If used, the physician inserts an esophageal introducer 92 through the throat and partially into the esophagus 10. The introducer 92 is pre-curved to follow the path from the mouth, through the pharynx, and into the esophagus 10. The introducer 92 also includes a mouthpiece 94, on which the patient bites to hold the introducer 92 in position. The introducer 92 provides an open, unobstructed path into the esophagus 10 and prevents spontaneous gag reflexes during the procedure.


The physician need not use the introducer 92. In this instance, a simple mouthpiece 94, upon which the patient bites, is used.


The physician preferably first conducts a diagnostic phase of the procedure, to localize the site to be treated. As FIG. 4a shows, a visualization device can be used for this purpose. The visualization device can comprise an endoscope 96, or other suitable visualizing mechanism, carried at the end of a flexible catheter tube 98. The catheter tube 98 for the endoscope 96 includes measured markings 97 along its length. The markings 97 indicate the distance between a given location along the catheter tube 98 and the endoscope 96.


The physician passes the catheter tube 98 through the patient's mouth and pharynx, and into the esophagus 10, while visualizing through the endoscope 96. Relating the alignment of the markings 97 to the mouthpiece 94, the physician can gauge, in either relative or absolute terms, the distance between the patient's mouth and the endoscope 96 in the esophagus 10. When the physician visualizes the desired treatment site (lower esophageal sphincter 18 or cardia 20) with the endoscope 96, the physician records the markings 97 that align with the mouthpiece 94.


The physician next begins the treatment phase of the procedure. As shown in FIG. 4b, the physician passes the catheter shaft 36 carrying the ultrasound transducer 34 through the introducer 92. For the passage, the expandable balloon 46 is in its collapsed condition. The physician can keep the endoscope 96 deployed for viewing the expansion and fit of the balloon 46 with the tissue 60, either separately deployed in a side-by-side relationship with the catheter shaft 36, or (as will be described later) by deployment through a lumen in the catheter shaft 36 or advancement of the catheter 32 through a lumen in the endoscope 96 itself and expansion of the balloon distal to the endoscope 96. If there is not enough space for side-by-side deployment of the endoscope 96, the physician deploys the endoscope 96 before and after expansion of the balloon 46.


As illustrated in FIG. 4b, the catheter shaft 36 includes measured markings 99 along its length. The measured markings 99 indicate the distance between a given location along the catheter shaft 36 and the ultrasound transducer 34. The markings 99 on the catheter shaft 36 correspond in spacing and scale with the measured markings 97 along the endoscope catheter tube 98. The physician can thereby relate the markings 99 on the catheter shaft 36 to gauge, in either relative or absolute terms, the location of the ultrasound transducer 34 inside the esophagus 10. When the markings 99 indicate that the ultrasound transducer 34 is at the desired location (earlier visualized by the endoscope 96), the physician stops passage of the ultrasound transducer 34. The ultrasound transducer 34 is now located at the site targeted for treatment.


In FIG. 5, the targeted site is shown to be the lower esophageal sphincter 18. In FIG. 6, the targeted site is shown to be the cardia 20 of the stomach 12.


Once located at the targeted site, the physician operates the syringe 48 to convey fluid or coupling gel into the expandable balloon 46. The balloon 46 expands to make intimate contact with the mucosal surface, either with the sphincter (see FIG. 5) or the cardia 20 (FIG. 6) over a length longer than where the acoustic energy 35 impacts the tissue. The balloon is expanded to temporarily dilate the lower esophageal sphincter 18 or cardia 20, to remove some or all the folds normally present in the mucosal surface, and to create a chamber 50 of fluid or gel through which the acoustic energy 35 couples to the tissue 60. The expanded balloon 46 also places the temperature sensors 52 in intimate contact with the mucosal surface.


The physician commands the energy generator 70 to apply electrical energy to the ultrasound transducer 34. The function of the ultrasound transducer 34 is to then convert the electrical energy to acoustic energy 35.


The energy heats the smooth muscle tissue below the mucosal lining. The generator 70 displays temperatures sensed by the temperature sensors 80 to monitor the application of energy. The physician may choose to reduce the energy output of the generator 70 if the temperatures exceed predetermined thresholds. The generator 70 may also automatically shutoff the power if temperature sensors 80 or other sensors in the catheter exceed safety limits.


Prior to energy delivery, it will most likely be necessary for the physician to make use of a fluid pump 80 to deliver cooling fluid 82 to keep the mucosal temperature below a safe threshold. This is discussed in more detail later. The pump 80 may be integrated into the generator unit 70 or operated as a separate unit.


Preferably, for a region of the lower esophageal sphincter 18 or cardia 20, energy is applied to achieve tissue temperatures in the smooth muscle tissue in the range of 55.degree. C. to 95.degree. C. In this way, lesions can typically be created at depths ranging from one 1 mm below the mucosal surface to as far as the outside wall of the esophagus 10. Typical acoustic energy densities range 10 to 100 W/cm.sup.2 as measured at the transducer surface. For focusing elements, the acoustic energy densities at the focal point are much higher.


It is desirable that the lesions possess sufficient volume to evoke tissue-healing processes accompanied by intervention of fibroblasts, myofibroblasts, macrophages, and other cells. The healing processes results in a contraction of tissue about the lesion, to decrease its volume or otherwise alter its biomechanical properties. Replacement of collagen by new collagen growth may also serve to bulk the wall of the sphincter. The healing processes naturally tighten the smooth muscle tissue in the sphincter 18 or cardia 20. Ultrasound energy typically penetrates deeper than is possibly by RF heating or thermal conduction alone.


With a full circumferential output of acoustic energy 35 from ultrasound transducer 34, it is possible to create a completely circumferential lesion 100 in the tissue 60 of the LES 18. To create greater lesion density in a given targeted tissue area, it is also desirable to create a pattern of multiple circumferential lesions 102a spaced axially along the length of the targeted treatment site in the LES 18 or cardia 20 (above and below the z-line 14, as shown in FIG. 7. Preferably, a pattern of 4 circumferential lesions 102a is desired spaced 1 cm apart, with 2 above the z-line 14, and 2 below; however, the safe and effective range may be just one or higher, depending on how the lesions form and heal. As shown in FIG. 6, the use of a “rear directed” ultrasound beam also allows treatment of the inferior aspect of the LES 18 and the cardia 20.


To limit the amount of tissue ablated, and still achieve the desired effect, it may be beneficial to spare and leave viable some circumferential sections of the esophageal wall. To this end, the ultrasound transducer 34 can be configured (embodiments of which are discussed in detail below) to emit ultrasound in discrete locations around the circumference. Various lesion patterns 102b can be achieved. A preferred pattern (shown in FIG. 8 for the esophagus 10) comprises several rings 104 of lesions 106 about 5 mm apart, each ring 104 comprising preferably 8 (potential range 1-16) lesions 106. For example, a preferred pattern 102b comprises six rings 104, 3 above and 3 below the z-line 14, each with eight lesions 106.


The physician can create a given ring pattern (either fully circumferential lesions or discrete lesions spaced around the circumference) 100 by expanding the balloon 46 with fluid or gel, pumping fluid 82 to cool the mucosal tissue interface as necessary, and delivering electrical energy from the generator 70 to produce acoustic energy 35 to the tissue 90. The lesions in a given ring (100 or 104) can be formed simultaneously with the same application of energy, or one-by-one, or in a desired combination. Additional rings of lesions can be created by advancing the ultrasound transducer 34 axially, gauging the ring separation by the markings 99 on the catheter shaft 36. Other, more random or eccentric patterns of lesions can be formed to achieve the desired density of lesions within a given targeted site.


The catheter 32 can also be configured such that once the balloon 46 is expanded in place, the distal shaft 36 upon which the transducer 34 is mounted can be advanced axially within the balloon 46 that creates the fluid chamber 35, without changing the position of the balloon 46. Preferably, the temperature sensor(s) 52 move with the transducer 34 to maintain their position relative to the energy beam 35.


The distal catheter shaft 36 can also be configured with multiple ultrasound transducers 34 and temperature sensors 52 along the distal axis in the fluid chamber 35 to allow multiple rings to be formed simultaneously or in any desired combination. They can also simply be formed one-by-one without having to adjust the axial position of the catheter 32.


To achieve certain heating effects, it may be necessary to utilize variations of the transducer, balloon, cooling system, and temperature monitoring. For instance, in order to prevent ablation of the mucosal lining of the esophagus 10, it may be necessary to either (or both) focus the ultrasound under the surface, or sufficiently cool the surface during energy delivery. To treat Barrett's Esophagus, the ultrasound may be focused at or just before the tissue surface. The balloon material, or an additional material adjacent to the balloon between the tissue and the transducer may be made of sufficient dimensions and acoustic properties to selectively absorb energy at the tissue interface. Materials having good acoustic absorption properties include silicone and polyurethane rubbers, and oil suspensions. Increasing the frequency of the transducer will also aid in confining acoustic absorption at the surface. Temperature monitoring provides feedback as to the how well the tissue is being heated and cooled.


The following sections describe various embodiments of the ultrasound transducer 34 design, the mounting of the ultrasound transducer 34, cooling configurations, and means of temperature monitoring.


Ultrasound Transducer Design Configurations: In one preferred embodiment, shown in FIG. 9, the transducer 34 is a cylinder of PZT (i.e., PZT-4, PZT-8) material 130. The material is plated on the inside and outside with a conductive metal, and poled to “flip”, or align, the dipoles in the PZT material 130 in a radial direction. This plating 120 allows for even distribution of an applied potential across the dipoles. It may also be necessary to apply a “seed” layer (i.e., sputtered gold) to the PZT 130 prior to plating to improve plating adhesion. The dipoles (and therefore the wall of the material) stretch and contract as the applied voltage is alternated. At or near the resonant frequency, acoustic waves (energy) 35 emanate in the radial direction from the entire circumference of the transducer. The length of the transducer can be selected to ablate wide or narrow regions of tissue. The cylinder is 5 mm long in best mode, but could be 2-20 mm long. Inner diameter is a function of the shaft size on which the transducer is mounted, typically ranging from 1 to 4 mm. The wall thickness is a function of the desired frequency. An 8 MHz transducer would require about a 0.011″ thick wall.


In another embodiment of the transducer 34 design, illustrated in FIG. 10, multiple strips 132 of PZT 130 or MEMS (Micro Electro Mechanical Systems—Sensant, Inc., San Leandro, Calif.) material are positioned around the circumference of the shaft to allow the user to ablate selected sectors. The strips 132 generally have a rectangular cross section, but could have other shapes. Multiple rows of strips could also be spaced axially along the longitudinal axis of the device. By ablating specific regions, the user may avoid collateral damage in sensitive areas, or ensure that some spots of viable tissue remain around the circumference after energy delivery. The strips 132 may be all connected in parallel for simultaneous operation from one source, individually wired for independent operation, or a combination such that some strips are activated together from one wire connection, while the others are activated from another common connection. In the latter case, for example, where 8 strips are arranged around the circumference, every other strip (every 90.degree.) could be activated at once, with the remaining strips (90.degree. C. apart, but 45.degree. C. from the previous strips) are activated at a different time. Another potential benefit of this multi-strip configuration is that simultaneous or phased operation of the strips 132 could allow for regions of constructive interference (focal regions 140) to enhance heating in certain regions around the circumference, deeper in the tissue. Phasing algorithms could be employed to enhance or “steer” the focal regions 140. Each strip 132 could also be formed as a curved x-section or be used in combination with a focusing lens to deliver multiple focal heating points 140 around the circumference.


The use of multiple strips 132 described above also allows the possibility to use the strips for imaging. The same strips could be used for imaging and ablation, or special strips mixed in with the ablation strips could be used for imaging. The special imaging strips may also be operated at a different frequency than the ablation strips. Since special imaging strips use lower power than ablation strips, they could be coated with special matching layers on the inside and outside as necessary, or be fitted with lensing material. The use of MEMs strips allows for designs where higher resolution “cells” on the strips could be made for more precise imaging. The MEMs design also allows for a mixture of ablation and imaging cells on one strip. Phasing algorithms could be employed to enhance the imaging.


In another embodiment of the transducer 34 design, shown in FIG. 11, a single cylindrical transducer 34 as previously described is subdivided into separate active longitudinal segments 134 arrayed around the circumference through the creation of discrete regions of inner plating 124 and outer plating 126. To accomplish this, longitudinal segments of the cylindrical PZT material 130 could be masked to isolate regions 127 from one another during the plating process (and any seed treatment, as applicable). Masking may be accomplished by applying wax, or by pressing a plastic material against the PZT 130 surface to prevent plating adhesion. Alternatively, the entire inner and outer surface could be plated followed by selective removal of the plating (by machining, grinding, sanding, etc.). The result is similar to that shown in FIG. 10, with the primary difference being that the transducer is not composed of multiple strips of PZT 130, but of one continuous unit of PZT 130 that has different active zones electrically isolated from one another. Ablating through all at once may provide regions of constructive interference (focal regions 140) deeper in the tissue. Phasing algorithms could also be employed to enhance the focal regions 140.


As described above, this transducer 34 can also be wired and controlled such that the user can ablate specific sectors, or ablate through all simultaneously. Different wiring conventions may be employed. Individual “+” and “−” leads may be applied to each pair of inner 124 and outer 126 plated regions. Alternatively, a common “ground” may be made by either shorting together all the inner leads, or all the outer leads and then wiring the remaining plated regions individually.


Similarly, it may only be necessary to mask (or remove) the plating on either the inner 124 or the outer 126 layers. Continuous plating on the inner region 124, for example, with one lead extending from it, is essentially the same as shorting together the individual sectors. However, there may be subtle performance differences (either desirable or not) created when poling the device with one plating surface continuous and the other sectored.


In addition to the concept illustrated in FIG. 11, it may be desirable to have a continuous plating ring 128 around either or both ends of the transducer 34, as shown in FIG. 12 (continuous plating shown on the proximal outer end only, with no discontinuities on the inner plating). This arrangement could be on either or both the inner and outer plating surface. This allows for one wire connection to drive the given transducer surface at once (the concept in FIG. 11 would require multiple wire connections).


Another means to achieve discrete active sectors in a single cylinder of PZT is to increase or decrease the wall thickness (from the resonant wall thickness) to create non-resonant and therefore inactive sectors. The entire inner and outer surface can be then plated after machining. As illustrated in FIG. 13, channels 150 are machined into the transducer to reduce the wall thickness from the resonant value. As an example, if the desired resonant wall thickness is 0.0110″, the transducer can be machined into a cylinder with a 0.0080″ wall thickness and then have channels 150 machined to reduce the wall thickness to a non-resonant value (i.e., 0.0090″). Thus, when the transducer 34 is driven at the frequency that resonates the 0.0110″ wall, the 0.0090″ walls will be non-resonant. Or the transducer 34 can be machined into a cylinder with a 0.015″ wall thickness, for example, and then have selective regions machined to the desired resonant wall thickness of, say, 0.0110″. Some transducer PZT material is formed through an injection molding or extrusion process. The PZT could then be formed with the desired channels 150 without machining.


Another way to achieve the effect of a discrete zone of resonance is to machine the cylinder such that the central core 160 is eccentric, as shown in FIG. 14. Thus different regions will have different wall thicknesses and thus different resonant frequencies.


It may be desirable to simply run one of the variable wall thickness transducers illustrated above at a given resonant frequency and allow the non-resonant walls be non-active. However, this does not allow the user to vary which circumferential sector is active. As a result, it may be desirable to also mask/remove the plating in the configurations with variable wall thickness and wire the sectors individually.


In another method of use, the user may gain control over which circumferential sector is active by changing the resonant frequency. Thus the transducer 34 could be machined (or molded or extruded) to different wall thicknesses that resonate at different frequencies. Thus, even if the plating 122 is continuous on each inner 124 and outer 126 surface, the user can operate different sectors at different frequencies. This is also the case for the embodiment shown in FIG. 10 where the individual strips 132 could be manufactured into different resonant thicknesses. There may be additional advantages of ensuring different depths of heating of different sectors by operating at different frequencies. Frequency sweeping or phasing may also be desirable.


For the above transducer designs, longitudinal divisions are discussed. It is conceivable that transverse or helical divisions would also be desirable. Also, while the nature of the invention relates to a cylindrical transducer, the general concepts of creating discrete zones of resonance can also be applied to other shapes (planar, curved, spherical, conical, etc.). There can also be many different plating patterns or channel patterns that are conceivable to achieve a particular energy output pattern or to serve specific manufacturing needs.


Except where specifically mentioned, the above transducer embodiments have a relatively uniform energy concentration as the ultrasound propagates into the tissue. The following transducer designs relate to configurations that focus the energy at some depth. This is desirable to minimize the heating of the tissue at the mucosal surface but create a lesion at some depth.


One means of focusing the energy is to apply a cover layer “lens” 170 (not shown) to the surface of the transducer in a geometry that causes focusing of the acoustic waves emanating from the surface of the transducer 34. The lens 170 is commonly formed out an acoustically transmissive epoxy that has a speed of sound different than the PZT material 130 and/or surrounding coupling medium. The lens 170 could be applied directly to the transducer, or positioned some distance away from it. Between the lens 170 and the transducer may be a coupling medium of water, gel, or similarly non-attenuating material. The lens could be suspended over (around) the transducer 34 within the balloon 46, or on the balloon itself.


In another embodiment, the cylindrical transducer 34 can be formed with a circular or parabolic cross section. As illustrated in FIG. 15, this design allows the beam to have focal regions 140 and cause higher energy intensities within the wall of the tissue.


In another embodiment shown in FIG. 16, angled strips or angled rings (cones) allow forward and/or rear projection of ultrasound (acoustic energy 35). Rearward projection of ultrasound 35 may be particularly useful to heat the underside of the LES 18 or cardia 20 when the transducer element 34 is positioned distal to the LES 18. Each cone could also have a concave or convex shape, or be used with a lensing material 170 to alter the beam shape. In combination with opposing angled strips or cones (forward 192 and rearward 194) the configuration allows for focal zones of heating 140.


In another embodiment, shown in FIG. 17, multiple rings (cylinders) of PZT transducers 34 would be useful to allow the user to change the ablation location without moving the catheter. This also allows for regions of constructive/destructive interference (focal regions 140) when run simultaneously. Anytime multiple elements are used, the phase of the individual elements may be varied to “steer” the most intense region of the beam in different directions. Rings could also have a slight convex shape to enhance the spread and overlap zones, or a concave shape to focus the beam from each ring. Pairs of opposing cones or angled strips (described above) could also be employed. Each ring could also be used in combination with a lensing material 170 to achieve the same goals.


Transducer Mounting: One particular challenge in designing transducers that deliver significant power (approximately 10 acoustic watts per cm.sup.2 at the transducer surface, or greater) is preventing the degradation of adhesives and other heat/vibration sensitive materials in proximity to the transducer. If degradation occurs, materials under or over the transducer can delaminate and cause voids that negatively affect the acoustic coupling and impedance of the transducer. In cases where air backing of the transducer is used, material degradation can lead to fluid infiltration into the air space that will compromise transducer performance. Some methods of preventing degradation are described below.


In FIG. 18, a preferred means of mounting the transducer 34 is to securely bond and seal (by welding or soldering) the transducer to a metal mounting member 200 that extends beyond the transducer edges. Adhesive attachments 202 can then be made between the mounting member 200 extensions remote to the transducer 34 itself. The mounting member(s) can provide the offsets from the underlying mounting structure 206 necessary to ensure air backing between the transducer 34 and the underlying mounting structure 206. One example of this is shown in FIG. 18 where metal rings 200 are mounted under the ends of the transducer 34. The metal rings 200 could also be attached to the top edges of the transducer 34, or to a plated end of the transducer. It may also be possible to mechanically compress the metal rings against the transducer edges. This could be accomplished through a swaging process or through the use of a shape-memory material such as nitenol. It may also be possible to use a single metal material under the transducer as the mounting member 200 that has depressions (i.e. grooves, holes, etc.) in the region under the transducer to ensure air backing. A porous metal or polymer could also be placed under the transducer 34 (with the option of being in contact with the transducer) to provide air backing.


In FIG. 19, another means of mounting the transducer 34 is to form the transducer 34 such that non-resonating portions 210 of the transducer 34 extend away from the central resonant section 212. The benefit is that the non-resonant regions 210 are integral with the resonant regions 212, but will not significantly heat or vibrate such that they can be safely attached to the underlying mounting structure 206 with adhesives 202. This could be accomplished by machining a transducer 34 such that the ends of the transducer are thicker (or thinner) than the center, as shown in FIG. 19.


As shown in FIG. 20, another option is to only plate the regions of the transducer 34 where output is desired, or interrupt the plating 122 such that there is no electrical conduction to the mounted ends 214 (conductor wires connected only to the inner plated regions).


The embodiments described in FIGS. 18-20 can also be combined as necessary to optimize the mounting integrity and transducer performance.


Cooling Design Configurations: Cooling flow may be necessary to 1) Prevent the transducer temperature from rising to levels that may impair performance, and 2) Prevent the mucosal lining of the sphincter from heating to the point of irreversible damage. The following embodiments describe the various means to meet these requirements.



FIG. 21 shows cooling fluid 82 being passed through a central lumen 53 and out the distal tip 37 to prevent heat buildup in the transducer 34. The central column of fluid 82 serves as a heat sink for the transducer 34.



FIG. 22 is similar to FIG. 21 except that the fluid 82 is recirculated within the central lumen 53 (actually a composition of two or more lumens), and not allowed to pass out the distal tip 37.



FIG. 23 (also shown a part of the preferred embodiment of FIG. 2) shows the fluid circulation path involving the balloon itself. The fluid enters through the balloon inflation lumen 51 and exits through one or more ports 224 in the central lumen 53, and then passes proximally out the central lumen 53. The advantage of this embodiment is that the balloon 46 itself is kept cool, and draws heat away from the mucosal lining of the sphincter. Pressure of the recirculating fluid 82 would have to be controlled within a tolerable range to keep the balloon 46 inflated the desired amount. Conceivably, the central lumen 53 could be the balloon inflation lumen, with the flow reversed with respect to that shown in FIG. 23. Similarly, the flow path does not necessarily require the exit of fluid in the central lumen 53 pass under the transducer 34—fluid 82 could return through a separate lumen located proximal to the transducer.


In another embodiment (not shown), the balloon could be made from a porous material that allowed the cooling fluid to exit directly through the wall of the balloon. Examples of materials used for the porous balloon include open cell foam, ePTFE, porous urethane or silicone, or a polymeric balloon with laser-drilled holes. It is also conceivable that if a conductive media, such as saline is used for the cooling fluid, and a ground patch attached to the patient, electrical RF energy from the outer plating of the transducer could be allowed to pass into the tissues and out to the ground patch, resulting in a combination of acoustic and RF heating of the tissue.



FIG. 24 shows the encapsulation of the transducer 34 within another lumen 240. This lumen 240 is optionally expandable, formed from a compliant or non-compliant balloon material 242 inside the outer balloon 46 (the lumen for inflating the outer balloon 46 is not shown). This allows a substantial volume of fluid to be recirculated within the lumen 240 without affecting the inflation pressure/shape of the outer balloon 46 in contact with the sphincter. Allowing a substantial inflation of this lumen decreases the heat capacity of the fluid in the balloon in contact with the sphincter and thus allows for more efficient cooling of the mucosal lining. Fluid 82 could also be allowed to exit the distal tip. It can also be imagined that a focusing lens material 170 previously described could be placed on the inner or outer layer of the lumen material 242 surrounding the transducer 34.


As is shown in FIG. 25, there can be an outer balloon 46 that allows circulation over the top of the inner balloon 242 to ensure rapid cooling at the interface. To ensure flow between the balloons, the inner balloon 242 can be inflated to a diameter less than the outer balloon 46. Flow 82 may be returned proximally or allowed to exit the distal tip. Another version of this embodiment could make use of raised standoffs 250 (not shown) either on the inside of the outer balloon 46 or the outside of the inner balloon 242, or both. The standoffs 250 could be raised bumps or splines. The standoffs 250 could be formed in the balloon material itself, from adhesive, or material placed between the balloons (i.e., plastic or metal mandrels). The standoffs 250 could be arranged longitudinally or circumferentially, or both. While not shown in a figure, it can be imagined that the outer balloon 46 shown in FIG. 25 may only need to encompass one side (i.e., the proximal end) of the inner balloon, allowing sufficient surface area for heat convection away from the primary (inner) balloon 242 that in this case may be in contact with the tissue. In the case of treating Barrett's Esophagus, the space between the two balloons may be filled with an oil suspension or other fluidic or thixotropic medium that has relatively high acoustic attenuation properties. The medium does not necessarily need to recirculate. The intent is that this space between the balloons will preferentially heat and necrose the intestinal metaplasia lining the esophagus.


In another embodiment, illustrated in FIG. 26, occluding members 260 are positioned proximal (260a) and distal (260b) to the transducer element for occluding the sphincter lumen 270. The occluding members 260 may also serve to dilate the sphincter region to a desired level. The occluding members 260 are capable of being expanded from a collapsed position (during catheter delivery) for occlusion. Each occluding member 260 is preferably an inflatable balloon, but could also be a self-expanding disk or foam material, or a wire cage covered in a polymer, or combination thereof. To deploy and withdraw a non-inflatable occluding member, either a self-expanding material could be expanded and compressed when deployed out and back in a sheath, or the occluding member could be housed within a braided or other cage-like material that could be alternatively cinched down or released using a pull mechanism tethered to the proximal end of the catheter 30. It may also be desirable for the occluding members 260 to have a “textured” surface to prevent slippage of the device. For example, adhesive spots could be applied to the outer surface of the balloon, or the self-expanding foam could be fashioned with outer ribs.


With the occluding members 260 expanded against the sphincter lumen, the chamber 278 formed between the balloons is then filled with a fluid or gel 280 that allows the acoustic energy 35 to couple to the tissue 60. To prevent heat damage to the mucosal lining ML of the tissue lumen 270, the fluid/gel 280 may be chilled and/or recirculated. Thus with cooling, the lesion formed within a target site T the tissue 60 is confined inside the tissue wall and not formed at the inner surface. This cooling/coupling fluid 280 may be routed into and out of the space between the occluding members with single entry and exit port, or with a plurality of ports. The ports can be configured (in number, size, and orientation) such that optimal or selective cooling of the mucosal surface is achieved. Note also that cooling/coupling fluid 280 routed over and/or under the transducer 34 helps keep the transducer cool and help prevent degradation in performance.


The transducer element(s) 34 may be any of those previously described. Output may be completely circumferential or applied at select regions around the circumference. It is also conceivable that other energy sources would work as well, including RF, microwave, laser, and cryogenic sources.


In the case where only certain sectors of tissue around the circumference are treated, it may be desirable to utilize another embodiment, shown in FIG. 27, of the above embodiment shown in FIG. 26. In addition to occluding the proximal and distal ends, such a design would use a material 290 to occlude regions of the chamber 278 formed between the distal and proximal occluding members 260. This would, in effect, create separate chambers 279 around the circumference between the distal and proximal occluding members 260, and allow for more controlled or greater degrees of cooling where energy is applied. The material occluding the chamber could be a compliant foam material or an inflatable balloon material attached to the balloon and shaft. The transducer would be designed to be active only where the chamber is not occluded.


Temperature Monitoring: The temperature at the interface between the tissue and the balloon may be monitored using thermocouples, thermistors, or optical temperature probes. Although any one of these could be used, for the illustration of various configurations below, only thermocouples will be discussed. The following concepts could be employed to measure temperature.


In one embodiment shown in FIG. 28, one or more splines 302, supporting one or more temperature sensors 52 per spline, run longitudinally over the outside of the balloon 46. On each spline 302 are routed one or more thermocouple conductors (actually a pair of wires) 306. The temperature sensor 52 is formed at the electrical junction formed between each wire pair in the conductor 306. The thermocouple conductor wires 306 could be bonded straight along the spline 302, or they could be wound or braided around the spline 302, or they could be routed through a central lumen in the spline 302.


At least one thermocouple sensor 52 aligned with the center of the ultrasound beam 35 is desired, but a linear array of thermocouple sensors 52 could also be formed to be sure at least one sensor 52 in the array is measuring the hottest temperature. Software in the generator 70 may be used to calculate and display the hottest and/or coldest temperature in the array. The thermocouple sensor 52 could be inside or flush with the spline 302; however, having the sensor formed in a bulb or prong on the tissue-side of the spline 302 is preferred to ensure it is indented into the tissue. It is also conceivable that a thermocouple placed on a slideable needle could be used to penetrate the tissue and measure the submucosal temperature.


Each spline 302 is preferably formed from a rigid material for adequate tensile strength, with the sensors 52 attached to it. Each individual spline 302 may also be formed from a braid of wires or fibers, or a braid of the thermocouple conductor wires 306 themselves. The splines 302 preferably have a rectangular cross section, but could also be round or oval in cross section. To facilitate deployment and alignment, the splines 302 may be made out a pre-shaped stainless steel or nitenol metal. One end of the spline 302 would be fixed to the catheter tip 37, while the proximal section would be slideable inside or alongside the catheter shaft 36 to allow it to move with the balloon 46 as the balloon inflates. The user may or may not be required to push the splines 302 (connected to a proximal actuator, not shown) forward to help them expand with the balloon 46.


The number of longitudinal splines could be anywhere from one to eight. If the transducer 34 output is sectored, the splines 302 ideally align with the active transducer elements.


In a related embodiment, a braided cage (not shown) could be substituted for the splines 302. The braided cage would be expandable in a manner similar to the splines 302. The braided cage could consist of any or a combination of the following: metal elements for structural integrity (i.e., stainless steel, nitenol), fibers (i.e., Dacron, Kevlar), and thermocouple conductor wires 306. The thermocouple sensors 52 could be bonded to or held within the braid. For integrity of the braid, it may be desirable for the thermocouple conductors 306 to continue distal to the thermocouple junction (sensor) 52. The number structural elements in the braid may be 4 to 24.


In another embodiment shown in FIG. 29, a design similar to the embodiment above is used, except the distal end of the spline 302 is connected to a compliant band 304 that stretches over the distal end of the balloon as the balloon inflates. The band 304 may be formed out of a low durometer material such as silicone, urethane, and the like. It may also be formed from a wound metal spring. The spline 302 proximal to the balloon may then be fixed within the catheter shaft 36. Of course the arrangement could be reversed with the spline 302 attached to the distal end of the balloon 46, and the compliant band 304 connected to the proximal shaft 36.


In another embodiment shown in FIG. 30, the sensors 52 are bonded with adhesive 308 to the inside of the balloon (in the path of the ultrasound beam 35). The adhesive 308 used is ideally a compliant material such as silicone or urethane if used with a compliant balloon. It may also be a cyanoacrylate, epoxy, or UV cured adhesive. The end of the conductor wire 306 at the location of the sensor 52 is preferably shaped into a ring or barb or the like to prevent the sensor from pulling out of the adhesive. Multiple sensors 52 may be arranged both circumferentially and longitudinally on the balloon 46 in the region of the ultrasound beam 35. Thermocouple conductor wires 306 would have sufficient slack inside the balloon 46 to expand as the balloon inflates.


In another embodiment (not shown), the thermocouple conductor wires are routed longitudinally through the middle of the balloon wall inside preformed channels.


In another embodiment shown in FIG. 31, the thermocouple sensors 52 are bonded to the outside of the balloon 46, with the conductor wires 306 routed through the wall of the balloon 46, in the radial direction, to the inside of the balloon 46 and lumens in the catheter shaft 36. The conductor wires 306 would have sufficient slack inside the balloon to expand as the balloon inflates. To achieve the wire routing, a small hole is punched in the balloon material, the conductor wire routed through, and the hole sealed with adhesive. The conductor wire could be coated in a material that is bondable with the balloon (i.e., the balloon material itself, or a compatible adhesive 308 as described for FIG. 30) prior to adhesive bonding to help ensure a reliable seal.


In another embodiment shown in FIGS. 32a-32c, the thermocouple sensors 52 mounted on the outer surface of the balloon (regardless of how the wires 306 are routed) are housed in raised bulbs 310 of adhesive 308 (or a molded section of the balloon material itself) that help ensure they are pushed into the tissue, allowing more accurate tissue temperature measurement that is less susceptible to the temperature gradient created by the fluid in the balloon. For compliant balloons, a stiff exposed sensor 52 could be housed in a bulb of compliant material with a split 312. As the balloon 46 inflates, the split 312 in the bulb 210 opens and exposes the sensor 52 to the tissue. As the balloon 46 deflates, the bulb 310 closes back over the sensor 52 and protects it during catheter manipulation in the body.


In another embodiment (not shown), an infrared sensor pointed toward the heat zone at the balloon-tissue interface could be configured inside the balloon to record temperatures in a non-contact means.


For the embodiments described in either FIG. 26 or FIG. 27 above, it may also be desirable to monitor the temperature of the tissue during energy delivery.


This would be best accomplished through the use of thermocouples aligned with the ultrasound beam emanating from the transducer. Each thermocouple would monitor the temperature of the mucosal surface to ensure that the appropriate amount of power is being delivered. Power can be decreased manually or though a feedback control mechanism to prevent heat damage to the mucosa, or the power can be increased to a predetermined safe mucosal temperature rise to ensure adequate power is being delivered to the submucosa.


As shown in FIG. 33, the thermocouple sensors 52 could be mounted on splines 302 similar in design, construction, and operation to those described previously. In this configuration, the splines 302 are expanded against the tissue without the use of an interior balloon. They are deployed before, during, or after the occlusion members 260 are expanded. The braided cage configuration described above may also be used.


In another embodiment (not shown), the splines 302 or braided cage containing the thermocouple sensors 52 could span over the top of either or both expandable occlusive members 260. If the occlusive members 260 are balloons, the balloons act to expand the cage outward and against the tissue. If the occlusive members 206 are made from a self-expanding foam or disk material, the cage can be used to contain the occlusive material 206 during advancement of the catheter by holding the individual components of the cage down against the shaft under tension. Once positioned at the site of interest, the cage can be manually expanded to allow the occlusive members 260 to self-expand.


The direction of ultrasound delivery to this point has mostly been described as moving radially into the tissues of the esophagus, LES, and/or gastric cardia. Other system embodiments described below may be employed to aid in using an ablation device that delivers energy in a variety of directions into the tissue. For example, the ablation device can be oriented such that the energy is applied through the longitudinal axis of the sphincter wall, as opposed to radially through the wall. This has the advantage of preventing energy from passing through the outer wall where surrounding structures, such as the vagal nerves, liver, aorta, and mediastinum reside. In addition, longitudinal lesions may help reduce the axial compliance of the sphincter, preventing it from shortening and thus delaying how soon it opens as the gastric pressure increases. The designs also lend themselves to use of a planar or partial arc transducer that can be more reliably fabricated into a thinner wall than a cylindrical (for circumferential output) transducer. This allows for operation at higher frequencies that increases energy attenuation in the tissue and limits the depth of penetration of the ultrasound energy. In this instance, radial direction of the energy is more feasible without damage to collateral structures. Finally, particular embodiments of this invention may make lesion formation in the gastric cardia easier than is possible with a circumferential system. Lesions created on the “underside” of the sphincter in the region of the gastric cardia may help reduce the compliance of the gastric sling fibers in this region. This may help delay opening of the sphincter as the stomach expands due to increases in gastric pressure. The region of the gastric cardia may also have more vagal innervation responsible for transient relaxations of the sphincter; the lesions would reduce this innervation.


As shown in FIG. 34a, the present invention relates to an ablation system 400 consisting of an ablation catheter 32 with an acoustic energy delivery element (ultrasound transducer) 34 mounted on the distal end of the catheter. The device is delivered transorally to the region of the LES 18. The system 400 consists of the following key components:


1. An overtube 500 having a balloon 502 attached to the distal opening 503.


2. An endoscope 96 having at least one therapeutic channel 518 greater than 2.8 mm.


3. A catheter 32 having a shaft 36 and a proximal hub/handle 38 containing fluid ports 40, electrical connectors 42, and optional central guidewire lumen port 44. The catheter also has an ultrasound transducer 34 on a mounting 37 that produces acoustic energy 35 at the distal end of the distal catheter shaft 520


4. An energy generator 70 and connector cable(s) 72 for driving the transducer and displaying temperature values


5. A fluid pump 80 delivering cooling fluid 82.



FIG. 34b illustrates a similar system where the ablation catheter 32 makes use of a transducer 34 designed to deliver acoustic energy radially (either circumferentially or in one or more discrete sectors) from the longitudinal axis. The catheter 32 can be moved with respect to the overtube balloon 502. The tip of the catheter may also be deflectable from an actuator on the proximal hub/handle 38.


While use of the catheter 32 through a channel in the endoscope 96 is preferred, it is conceivable that the catheter 32 could be deployed through the overtube 500 without the use of the endoscope 96.


The preferred method of ablation treatment is illustrated in FIGS. 35-39. In FIG. 35, an overtube device 500 having a peanut-shaped balloon 502 is preloaded over an endoscope 96. The balloon 502 is preferably made of a compliant material such as silicone or polyurethane, but could also be a material such as polyethylene or PET. The wall thickness of the balloon is preferably thicker in the middle of the “peanut” to limit the degree of radial expansion compared to the proximal and distal sections. Alternatively the middle of the balloon is simply blown or molded to a smaller diameter. The tip of the overtube balloon 502 is fitted with a relatively rigid nipple-shaped dome 504 that allows a snug fit with the tip of the endoscope. The dome 504 may be an integral, thickened portion of the balloon itself, or a separate component that the balloon is bonded to. It is conceivable that to aid seating the endoscope 96 in the dome 504 and make later release more reliable, the tip of the endoscope could be secured to the dome with the aid of one of the available endoscope channels. For instance, suction from a channel of the endoscope 96 could be applied to hold the dome against the endoscope tip, or a screw or barb or other grasping mechanism could be advanced through the channel to secure the dome tip to the tip of the endoscope. Also, vacuum may be applied to the balloon 502 using the lumen of the overtube 500, or from a lumen of the endoscope 96, to fold the balloon 502 down onto the endoscope. The proximal end of the overtube 502 is fitted with appropriate stasis valves to prevent leakage out the proximal end. The balloon 502 and/or the dome 504 should be transparent to allow visualization of tissue structures through the balloon wall.


An optional embodiment (not shown) would be the use of a vent tube alongside the overtube 500 and overtube balloon 520 to allow air in the stomach to vent out of the patient. The tube could be positioned completely separate from the overtube or advanced through an optional lumen in the overtube, exiting just proximal to the overtube balloon 520. The distal end of the vent tube would be positioned in the stomach 20 distal to the overtube balloon 520. The tube is preferably relatively stiff at the proximal end (for push transmission), and floppy at the distal end so that it is atraumatic and conforms well to the overtube balloon 520 as the balloon entraps the vent tube against the tissue. While the inner diameter of the vent tube needs to be only on the order of 0.005″ to vent air, larger inner diameters up to 0.042″ may be used to speed the aspiration of fluids or allow the passage of a guide wire (for ease in placement). The wall thickness may be 0.003″ to 0.010″, preferably, 0.004″. The wall of the tube may be a solid material, or a composite of plastic and adhesives and/or stainless steel or nitenol wires or Dacron fibers. The wall may consist of stainless steel, nitenol, or a plastic such as polyurethane, pebax, polyethylene, PET, polyimide, or PVC.


With the endoscope 96 seated in the dome 504 of the balloon 502, the overtube 500 and endoscope 96 are advanced down the esophagus 10 to the region of the LES 18. As illustrated in FIG. 36, using endoscopy visualization, and retracting the endoscope as necessary, the balloon is positioned so that the peanut shape straddles the LES 18.


The balloon is then inflated with a fluid medium (water, saline, contrast, etc.) as illustrated in FIG. 37. Inflation is performed preferably through the lumen of the overtube, although an available channel in the endoscope 96, or lumens in the ablation catheter 32 may also be used. The shape of the balloon allows it to conform to the contours of the esophagus at, and on either side of, the LES. The shape also helps stabilize the balloon at the LES. The balloon is inflated to a diameter that allows safe dilatation of the folds in the esophagus. The nominal inflated diameter of the proximal section 510 should be 20 mm, with a range of 15-30 mm. The distal section 512 can be larger, nominally 40 mm and a range of 15-50 mm. Diameter may be assessed by fluid volume, pressure, endoscopic visualization, or fluoroscopic visualization. The balloon and the fluid inside form a “coupling chamber” that allows ultrasound energy to be transmitted to the tissue from inside the balloon. Addition of contrast to the fluid allows fluoroscopic visualization of the shape and diameter.


With the balloon inflated, the distal shaft 520 of the ablation catheter 32 is advanced out of the endoscope channel 518, as shown in FIGS. 38a and 38b. Mounted on the distal shaft 520 is an ultrasound transducer 34. The transducer 34 is preferably a cylinder with only one segment of the circumference active. Other transducers have been described in provisional patent application 60/393,339 and are incorporated by reference herein. An external manipulation member (hereafter called pull wire) 530 is positioned on the side of the distal shaft 520 opposite the active transducer segment. The distal end of the pull wire 530 is attached to a hinge (or weld-joint 528 at the catheter tip, and the proximal end is routed through a lumen orifice 532 in the distal catheter shaft 520 and out the proximal end of the catheter to an actuator on the hub/handle 38. As the pull wire 530 is tensioned, a soft, kink resistant section 522 of the distal shaft 520 forms a tight bend that allows the transducer to be oriented at the desired angle inside the balloon 502. Compression of the pull wire straightens the distal shaft 520 and may also bend it in the opposite direction. The endoscope and/or fluoroscope may be used to determine the proper orientation of the transducer relative to the tissue.


With the transducer 34 oriented towards the tissue, cooling flow circulation is initiated as shown in FIG. 38b, to prevent heating of the mucosa during subsequent energy delivery. Chilled fluid 82 from the pump 80 is preferably routed through a lumen under/behind the transducer, out the distal orifice 526 and back through the proximal (to the transducer) orifice 524 to a separate lumen returning to the pump 80 or other reservoir. Alternatively, or in addition, chilled fluid may be circulated via the overtube lumen or a lumen in the endoscope.


As shown in FIG. 39, energy from the generator 70 is applied to the transducer 54, which creates a beam of acoustic energy 35 directed towards the LES tissue 18. The transducer frequency, power level, and power duration are chosen to create a lesion 550a of a desirable size. The catheter 32 may be torqued and the pullwire 530 adjusted to reorient the transducer to another location around the circumference and/or the length of the LES region, where energy delivery and lesion creation are repeated. Ideally, each lesion is formed for about 5-10 mm down the axial length of the LES at a radial depth of 3-8 mm. As shown in FIG. 40, the transducer can also be directed towards the LES 18 from within the stomach 12. Also, from the same position, the transducer can be oriented to ablate the gastric cardia 20, just beyond the LES 18. Lesions in the gastric cardia might be more effective in ablating vagal afferent nerve fibers responsible for transient relaxations of the LES and also reduce the compliance of the gastric sling fibers to delay sphincter opening during gastric distension.



FIG. 41 shows another embodiment of the invention where the transducer 34 is instead (or in addition to) positioned at the tip of the ablation catheter to direct energy in the same direction as the axis of the catheter.



FIG. 42 shows another embodiment where a smaller balloon 502′ is fitted on the tip of the overtube 500 to contain the distal portion of the ablation catheter 32. The distal end of the overtube shaft 500 in this case is aligned with the distal end of the endoscope 96 and may be deflected with the endoscope 96. Also as shown in FIG. 42, the pull wire may be routed through a separate channel of the endoscope (the wire would need to be back-loaded through the endoscope before it is inserted into the overtube).



FIG. 43 shows another embodiment where the balloon 502″ is attached to the distal shaft 520 of the catheter 32, and no overtube is used. The distal end of pull wire 530 may be attached to the outside of the shaft proximal to the balloon, or fixed inside the distal shaft.



FIG. 44 shows another embodiment of the overtube 500 where a distal member 501 extends from the distal opening of the overtube to the distal end of the balloon 502. The distal end of the balloon 502 is bonded to the distal end of the member 501. The member 501 may have one or more lumens to allow passage of a guide wire 400, and for inflation/deflation of the balloon, and/or circulating cooling fluid within the balloon. The distal opening of member 501 may also be used to vent air from the stomach. The endoscope 96 carrying catheter 32 may be advanced through the main channel of the overtube 500 as described previously.



FIG. 45 shows another embodiment of the overtube 500 employing the use of a doughnut shaped balloon 502e attached to the distal end of the overtube. The doughnut shape allows for a central lumen in the balloon. This may be important to vent air from the stomach 12 or allow passage of the endoscope distal to the balloon. The doughnut shape also provides a good reference to the position of the inferior LES when inflated in the stomach and pulled back against the bottom of the LES.



FIG. 46 illustrates the use of the ablation catheter 32 with the overtube having a doughnut shaped balloon. The distal end of the ablation catheter 32 is advanced through the center of the doughnut shaped balloon 502e. With the transducer 34 aligned in the desired location, the ablation catheter balloon 46 is inflated inside the overtube balloon 502e. With both the overtube balloon and 502e and the ablation catheter balloon 46 filled with an adequate coupling fluid (i.e., water), the ultrasound energy is able to propagate relatively undamped until it reaches the tissue of the LES 18 or gastric cardia 20. The fluid inside either or both the overtube balloon 502e or the ablation catheter balloon 46 may be recirculated and chilled to prevent overheating of the transducer 34 or the mucosa. Conceivably, the overtube 500 could have a window opening (not shown) proximal to the doughnut shaped balloon 502e. This would allow the balloon 46 of the ablation catheter to inflate out of the inner lumen of the overtube proximal to the overtube balloon 502e.



FIG. 47 shows another embodiment where the peanut shaped balloon 502 is mounted on the distal ablation catheter shaft 520, and no overtube is used. The ablation catheter may or may not be passed through an endoscope 96. If not passed through an endoscope, an endoscope is advanced alongside the catheter shaft, or positioned at the desired location and the distance noted before it is removed and the ablation catheter inserted the same distance. Transducers 34 are mounted on the distal shaft 520 under to balloon at locations either or both distal and proximal to the LES 18 (the sunken region of the peanut balloon 502). The transducers may be hinged to the side of the shaft and at point 229, and hinged at the other end 528 where a pull wire is attached. The pull wire 530 is routed through the shaft 520 to an actuator on the proximal end of the device. Push and pull of the pull wire 530 may allow swiveling of the transducer to create lesions 551a-551d. The transducers may also be driven simultaneously while angled to focus at an intersection point within the wall of the LES 18.


Other embodiments focused on a means to change the angle of the transducer are illustrated in FIGS. 48a-48d. In FIG. 48a, the transducer is mounted on a shaft member 521, which is advanced out of a lumen in the distal shaft 520 of the ablation catheter 32. The shaft 521 may have a set curve or be deflectable with an internal pull wire. It can be seated in a channel 525 in shaft 520 during advancement and retraction. The transducer 34 can be uni- or multidirectional. In FIG. 48b, the shaft 521 continues distal to the transducer where it is fixed inside shaft 520. Pushing and pulling on the proximal shaft 520 causes a prolapse proximal to the transducer at a soft, kink-resistant point 523. In FIG. 48c, pull wire 530 is attached to the proximal end of the transducer at hinge 528. The “pull wire” is pushed forward to increase the transducer angle, and pulled back to reduce the angle. In FIG. 48d, the transducer 34 is angulated by inflating a bladder 527 under the transducer. A floppy tether 529 may be tensioned to fully seat the transducer 34 and bladder 527 into groove 525 during insertion and removal.


In another embodiment shown in FIG. 49a, an endoscope 96 with two available channels is advanced down the esophagus 10 to the region of the LES 18. The distal shaft 520 of ablation catheter is advanced out of one of the available channels of the endoscope 96 to the region of the LES 18 to be treated. Mounted on the distal shaft 520 is an ultrasound transducer 34. The transducer 34 is preferably mounted to deliver a beam of acoustic energy in the same direction as the catheter's longitudinal axis, but could also be designed to deliver energy at other angles to the axis. The transducer is optionally surrounded distally by a coupling chamber 570, consisting of a rigid or flexible membrane 571 filled with an acoustic coupling medium (e.g., water, saline, gel). The thickness of the membrane 571 where the ultrasound energy passes is preferably less than one-quarter the wavelength of the ultrasound to prevent transmission loss. One or more temperature sensors 569 may be mounted on the tip of the membrane 571 in the path of the ultrasound beam 35 to monitor temperature of the mucosa to prevent overheating.


An occlusion balloon catheter 560 consisting of a catheter shaft 561 and balloon 562 is advanced through another available channel of the endoscope 96 and distal to the LES 18. The balloon 562 is inflated (with air or water via a lumen in the catheter, exiting at port 563 inside the balloon) in the stomach 12 to a diameter larger than the LES opening and then pulled back against the LES to create a seal. Fluid 565 (e.g., water, saline) is injected through a lumen in catheter 560, exiting from a port 564 proximal to the balloon, to fill the region of the esophagus 10 proximal to the LES 18. This provides a means of ensuring acoustic energy is coupled to the tissue as well as providing a means of cooling the mucosa to prevent heat damage. The fluid 565 may alternatively or additionally be infused through a lumen in the endoscope 96. Circulation of the fluid 565 may also be accomplished through multiple lumens in shaft 561 of catheter 560, or endoscope 96.


As shown in FIG. 49b, an overtube 500 having a balloon 572 bonded to the distal portion of the overtube shaft may be used to create a proximal seal to contain the fluid 565 infused in the region of the LES 18 (the balloon catheter 560 would continue to be used to contain the fluid 565 at the distal portion of the LES 18). As illustrated in FIG. 49b and FIGS. 49c-e, a stasis valve 573 on the tip of the overtube may be used to prevent fluid from migrating up the space between the endoscope and overtube, as well as to prevent scraping the mucosa when the overtube is moved relative to the endoscope. The valve 573 is compressible (formed from silicone rubber or polyurethane) to accommodate a range of endoscope outer diameters. The proximal end of overtube 500 may be fitted with a similar stasis valve, or o-ring 574 which may be manually compressed by turning a threaded nut 575. A side port luer 576 may be used to flush the lumen of the overtube 500.


Referring back to FIG. 49a, once the fluid 565 is infused, the transducer 34 is energized to deliver ultrasound energy 35 to the region of the LES 18. The energy 35 is delivered for a sufficient time and energy to create a lesion 575a in the tissue in the region of the LES 18. The process may be repeated multiple times around the circumference and/or axis of the LES 18 to create additional lesions, such as 575b.


In another embodiment shown in FIG. 50, the ablation catheter 32 is configured similar to that shown in FIG. 51. The catheter 32 is designed to be preloaded in the endoscope 96 such that an extended portion of the shaft 572 distal to the transducer 34 runs from the distal endoscope, out through the proximal end. This allows manipulation of two shaft elements, 570 and 572, proximal and distal to the transducer, respectively, to change the orientation of the transducer 34. The transducer 34 in this configuration is elongated such that its width is approximately the same as the diameter of the catheter shaft, and the length is in the range of 3-10 mm. An occlusion balloon catheter 560 is again positioned distal to the LES, but runs alongside the endoscope 96, not through it. An overtube 500 with balloon 572 may be used in a manner similar to that of FIG. 49b. As described for FIGS. 49a and 49b, fluid 565 is infused into the region of the LES 18 and acoustic energy 35 is delivered from the transducer 34 into the tissue to form lesions in various locations such as 576a and 576b.


In another embodiment shown in FIG. 51, the distal shaft 520 of ablation catheter 32 is advanced out of an endoscope 96 in the region of the LES 18. In this embodiment, the endoscope only requires one free channel, that dedicated to the ablation catheter 32. The distal shaft 520 of the catheter 32 is fitted with a transducer 34, mounted along the side of the of the catheter shaft. The transducer is surrounded by a membrane 580 with features and function similar to that described for FIG. 49a to aid in coupling of the ultrasound energy to the tissue. The fluid or gel in the membrane may be recirculated to keep the transducer and mucosa cool. Mounted to the opposite side of the shaft 520 from the transducer 34 is an expandable member 582 designed to force the membrane 580 surrounding the transducer 34 securely against the tissue. The expandable member 582 is preferably a balloon, but could also consist of one or more moveable splines designed to bow against the tissue. An internal pull wire mechanism (not shown) connected to a proximal actuator could also be employed to aid in deflecting the distal shaft 520 against the tissue in the region of the LES 18. Once in position against the tissue, ultrasound energy 35 is delivered from the transducer 34 to form lesions in various positions in proximity to the LES, such as 577a and 577b.


In another embodiment shown in FIG. 52a and FIG. 52b, an ablation catheter 32 is advanced to the region of the LES. Accurate positioning at the LES is accomplished by using markings on the shaft corresponding to previous use of an endoscope, or placing an endoscope alongside the shaft of the ablation catheter. Constructed on the distal end of catheter shaft 520 is a tissue chamber 590 designed to accept a portion of the muscle wall in the region of the LES 18. The tissue chamber may measure 5-25 mm long and 3-10 mm deep. Constructed proximal to the tissue chamber 590 is a transducer assembly chamber 592. Within chamber 592 a transducer assembly 594 is slideable via a piston 596 connected to an actuator on the proximal end of the catheter 32. The transducer assembly 594 consists of a transducer 34 mounted with proximal air backing and a distal coupling chamber 598 formed by a membrane 599 (similar in form and function to that described for FIG. 49). Cooling fluid 600 may be circulated in and out of the chamber 598. Using the piston 596 the assembly may be pushed down onto the tissue drawn into the tissue chamber 590. To aid in drawing the tissue into the chamber 590 and securing it there, suction from a plurality ports 601 may be employed. The use on an expandable member 602 (balloon or splines) mounted opposite to the chamber may aid in forcing the catheter into the tissue (and thus the tissue into the chamber 590).


At the distal end of the chamber is an optional chamber 604 that may also accept circulated cooling fluid 600 to keep the distal end of the mucosa from overheating. Distal to optional chamber 604 is an element 606 that can be configured to absorb ultrasound energy not absorbed by the tissue. This may consist of a highly attenuating material such as silicone or polyurethane rubber. Alternatively, element 606 could be another transducer 34 that directs energy into the tissue towards that coming from the transducer assembly 594 to increase the heating within the tissue. An atraumatic tip 608 is attached to the distal tip of the catheter 32. Once the tissue is pulled into the coupling chamber 590, the transducer assembly 594 pushed against the tissue and infused with cooling fluid 600, ultrasound energy 35 is delivered into the tissue to form a lesion 610.


An alternative embodiment of the device described in FIG. 52 would be to not require the transducer assembly 594 to be moveable, and thereby eliminate the need for the piston 596. The push force onto the tissue could be accomplished by designing the membrane 599 to be outward expandable. Also, an internal pull wire mechanism (not shown) attached to the distal tip of the catheter and connected to a proximal actuator could also be employed to aid in deflecting the distal shaft 520 against the tissue in the region of the LES 18. More specifically, the pull wire may be used to curl the distal tip 608 (and attached segments 606 and 604 under and against the LES tissue.


Other means may be used in addition to or in place of that described for FIG. 52 to draw the tissue into the tissue chamber. FIG. 53a illustrates grasping mechanisms 620 actuated by pull wires 622 connected to an actuator at the proximal end of catheter 32. The grasping mechanisms 620 are formed from a metal or hard plastic and contain frictional tread 624 to assist in holding the slippery tissue. They are also contained within the chamber 590 and hollow in the middle so as to not interfere with the ultrasound energy. The grasping mechanisms 630 illustrated in FIG. 53b are similar to FIG. 53a except that they swing out from the catheter shaft to help pull more tissue into the chamber 590. Additional tread 632 on the bottom (distal) end of the chamber would aid in holding the tissue in place. FIG. 53c shows preformed wire (i.e., stainless steel or nitenol) being advanced out of the catheter shaft to pinch the tissue and help force it into the tissue chamber 590. In FIG. 53d, two “partial doughnut” balloons are inflated to help pinch and push the tissue into the tissue chamber.

Claims
  • 1. A method of intraluminal ablation of nerve tissue surrounding a bodily lumen of a subject, comprising: delivering an ablation device within a bodily lumen of a subject, the ablation device comprising a catheter having a fluid passage, a balloon and an ultrasound transducer disposed along a distal end of the catheter within the balloon, the ultrasound transducer having a resonating region with a first diameter and an integral circumferential step that forms a non-resonating region with a second diameter, the fluid passage being in fluid communication with the balloon, and wherein the integral circumferential step is at an end of the ultrasound transducer;advancing the ablation device within the bodily lumen to position the ultrasound transducer adjacent target nerve tissue of the subject, wherein the target nerve tissue is positioned in nerve pathways that run adjacent the bodily lumen;delivering a cooling fluid through the fluid passage to inflate the balloon to a circular cross-sectional shape, coaxial with the ultrasound transducer, to center the ultrasound transducer within the bodily lumen so as to locate the ultrasound transducer at a pre-determined position relative to a wall of the bodily lumen;circulating the cooling fluid through an interior of the balloon via the fluid passage to remove heat from the ultrasound transducer and to reduce a likelihood of heating a lining of the bodily lumen to the point of irreversible damage; andactivating the ultrasound transducer to excite the resonating region to deliver ultrasonic energy radially outwardly through the balloon and the wall of the bodily lumen while cooling fluid is circulated through the interior of the balloon, the ultrasound energy being delivered around an entire circumference of the bodily lumen to at least partially ablate the target nerve tissue in a uniform annulus of tissue at a depth of 1 mm to 10 mm from the wall of the bodily lumen, the non-resonating region reducing the transmission of ultrasonic energy to the distal end of the catheter.
  • 2. The method of claim 1, wherein delivering the cooling fluid to the balloon comprises providing fluid within an interior of the balloon so that the balloon at least partially engages the wall of the bodily lumen.
  • 3. The method of claim 1, wherein energizing the ultrasound transducer raises a temperature of a targeted anatomical tissue by 55° C. to 95° C.
  • 4. The method of claim 1, wherein energizing the ultrasound transducer raises a temperature of a targeted anatomical tissue by 60° C. to 80° C.
  • 5. The method of claim 1, wherein the balloon comprises at least one compliant material.
  • 6. The method of claim 1, wherein the balloon comprises at least one non-compliant material.
  • 7. A method of intraluminal ablation of nerve tissue surrounding a bodily lumen of a subject, comprising; inserting an ablation device within a bodily lumen of a subject, the ablation device comprising a catheter, a balloon and ultrasound transducer disposed on a distal region of the catheter within the balloon, the ultrasound transducer having a resonating region of a first diameter and an integral circumferential step forming a non-resonating region of a second diameter, wherein the integral circumferential step is at an end of the ultrasound transducer;advancing the ablation device within the bodily lumen to position the ultrasound transducer near a target anatomical location of the subject, wherein the target nerve tissue is positioned in nerve pathways that run adjacent the bodily lumen along the target anatomical location;at least partially inflating the balloon by delivering a fluid into an interior of the balloon to reduce the likelihood of heating an inner lining of the bodily lumen to the point of irreversible damage, the balloon when inflated having a circular cross-sectional shape coaxial with the ultrasound transducer and that radially centers the ultrasound transducer within the bodily lumen at a pre-determined position relative to a wall of the bodily lumen; andactivating the ultrasound transducer to excite the resonating region to emit ultrasonic energy outwardly toward and through a wall of the bodily lumen, around an entire circumference of the bodily lumen, so as to ablate nerve tissue positioned adjacent the wall of the bodily lumen within a uniform annulus of tissue.
  • 8. The method of claim 7, further comprising circulating a fluid through an interior of the balloon during activation of the ultrasound transducer to remove heat from the ultrasound transducer.
  • 9. The method of claim 7, wherein at least partially inflating the balloon comprises providing fluid within the interior of the balloon so that the balloon at least partially contacts the wall of the bodily lumen.
  • 10. The method of claim 7, wherein activating the ultrasound transducer raises a temperature of a targeted anatomical tissue by 55° C. to 95° C.
  • 11. A method of intraluminal ablation of nerve tissue surrounding a bodily lumen of a subject, comprising: inserting an ablation device, within a bodily lumen of a subject, the ablation device comprising a catheter having a distal region, a balloon disposed on the distal region and an ultrasound transducer disposed within the balloon, the ultrasound transducer having a resonating region of a first diameter and an integral circumferential step forming a non-resonating region of a second diameter, wherein the integral circumferential step is at an end of the ultrasound transducer;advancing the ablation device within the bodily lumen to position the ultrasound transducer near a target anatomical location of the subject, wherein the target nerve tissue is positioned in nerve pathways that run adjacent the bodily lumen along the location of the ultrasound transducer;at least partially inflating the balloon by circulating a cooling fluid through the interior of the balloon to transfer heat away from the ultrasound transducer to reduce the likelihood of heating an inner lining of the bodily lumen to the point of irreversible damage, the balloon, when inflated, centering the ultrasound transducer within the bodily lumen at a pre-determined position relative to a wall of the bodily lumen;activating the ultrasound transducer to excite the resonating region to deliver ultrasonic energy outwardly toward a wall of the bodily lumen, around an entire circumference of the bodily lumen, to ablate nerve tissue positioned adjacent the wall of the bodily lumen in an annulus of tissue having a depth of 1 mm to 10 mm from the wall of the bodily lumen.
  • 12. The method of claim 11, wherein at least partially inflating the balloon comprises providing cooling fluid within the interior of the balloon so that the balloon at least partially contacts the wall of the bodily lumen.
  • 13. The method of claim 11, wherein circulating a cooling fluid within the interior of the balloon comprises circulating the cooling fluid through at least two separate fluid passages of the catheter.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 10/611,838 filed Jun. 30, 2003, which is a non-provisional of U.S. patent application Ser. No. 60/419,317 filed Oct. 16, 2002, which contained the entire content of prior Provisional Application No. 60/393,339 filed on Jul. 1, 2002, with additional material added, the full disclosures of which are incorporated herein by reference.

US Referenced Citations (743)
Number Name Date Kind
3168659 Bayre et al. Feb 1965 A
4055190 Tany et al. Oct 1977 A
4084582 Nigam Apr 1978 A
4185501 Proudian et al. Jan 1980 A
4194510 Proudian Mar 1980 A
4338942 Fogarty Jul 1982 A
4381007 Doss Apr 1983 A
4387720 Miller Jun 1983 A
4391281 Green Jul 1983 A
4402307 Hanson et al. Sep 1983 A
4403612 Fogarty Sep 1983 A
4422447 Schiff Dec 1983 A
4433692 Baba Feb 1984 A
4602624 Naples et al. Jul 1986 A
4643186 Rosen et al. Feb 1987 A
4650466 Luther Mar 1987 A
4672961 Davies Jun 1987 A
4680499 Umemura et al. Jul 1987 A
4685334 Latimer Aug 1987 A
4691714 Wong et al. Sep 1987 A
4722347 Abrams et al. Feb 1988 A
4744366 Jang May 1988 A
4785815 Cohen Nov 1988 A
4800316 Ju-Zhen Jan 1989 A
4813934 Engelson et al. Mar 1989 A
4841977 Griffith et al. Jun 1989 A
4869263 Segal et al. Sep 1989 A
4914510 Brennesholtz et al. Apr 1990 A
4945912 Langberg Aug 1990 A
4972826 Koehler et al. Nov 1990 A
4976711 Parins et al. Dec 1990 A
4983169 Furukawa Jan 1991 A
5006119 Acker et al. Apr 1991 A
5019034 Weaver et al. May 1991 A
5104393 Isner Apr 1992 A
5105116 Okamoto et al. Apr 1992 A
5114423 Kasprzyk et al. May 1992 A
5117831 Jang et al. Jun 1992 A
5125928 Parins et al. Jun 1992 A
5135001 Sinofsky et al. Aug 1992 A
5140987 Schuger Aug 1992 A
5160336 Favre Nov 1992 A
5167233 Eberle et al. Dec 1992 A
5175711 Fujita et al. Dec 1992 A
5203326 Collins et al. Apr 1993 A
5209299 Ayres May 1993 A
5213098 Bennett et al. May 1993 A
5217454 Khoury Jun 1993 A
5226421 Frisbie et al. Jul 1993 A
5226430 Spears et al. Jul 1993 A
5240005 Viebach Aug 1993 A
5242438 Saadatmanesh et al. Sep 1993 A
5242441 Avitall Sep 1993 A
5246438 Langberg Sep 1993 A
5269291 Carter Dec 1993 A
5281213 Milder et al. Jan 1994 A
5281218 Imran Jan 1994 A
5282785 Shapland et al. Feb 1994 A
5286254 Shapland et al. Feb 1994 A
5293868 Nardella Mar 1994 A
5295484 Marcus et al. Mar 1994 A
5300068 Rosar et al. Apr 1994 A
5304120 Crandell et al. Apr 1994 A
5305731 Buchholtz Apr 1994 A
5305755 Nakao Apr 1994 A
5324255 Passafaro et al. Jun 1994 A
5324259 Taylor et al. Jun 1994 A
5334193 Nardella Aug 1994 A
5338295 Cornelius et al. Aug 1994 A
5342292 Nita et al. Aug 1994 A
5348010 Schnall et al. Sep 1994 A
5364388 Koziol Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5385148 Lesh et al. Jan 1995 A
5391197 Burdette Feb 1995 A
5400267 Denen et al. Mar 1995 A
5415654 Daikuzono May 1995 A
5419335 Hartmann et al. May 1995 A
5421338 Crowley et al. Jun 1995 A
5423319 Seyed-Bolorforosh Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423755 Kesten Jun 1995 A
5423807 Milder Jun 1995 A
5431663 Carter Jul 1995 A
5452733 Sterman et al. Sep 1995 A
5454782 Perkins Oct 1995 A
5456259 Barlow Oct 1995 A
5458568 Racchini et al. Oct 1995 A
5458626 Krause Oct 1995 A
5468239 Tanner et al. Nov 1995 A
5470352 Rappaport Nov 1995 A
5471988 Fuijo Dec 1995 A
5472406 de la Torre et al. Dec 1995 A
5477736 Lorraine Dec 1995 A
5484400 Edwards et al. Jan 1996 A
5488955 Dias Feb 1996 A
5492532 Ryan et al. Feb 1996 A
5498238 Shapland et al. Mar 1996 A
5499971 Shapland et al. Mar 1996 A
5505700 Leone et al. Apr 1996 A
5507724 Hofmann et al. Apr 1996 A
5513639 Satomi et al. May 1996 A
5549644 Lundquist et al. Aug 1996 A
5553611 Budd et al. Sep 1996 A
5562720 Stern et al. Oct 1996 A
5569198 Racchini et al. Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571147 Sluijter et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575787 Abela et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5596989 Morita Jan 1997 A
5599345 Edwards et al. Feb 1997 A
5606974 Castellano et al. Mar 1997 A
5620479 Diederich Apr 1997 A
5626576 Janssen May 1997 A
5628730 Shapland et al. May 1997 A
5630837 Crowley May 1997 A
5634899 Shapland et al. Jun 1997 A
5643279 Trotta Jul 1997 A
5655539 Wang et al. Aug 1997 A
5669932 Fischell et al. Sep 1997 A
5672174 Gough et al. Sep 1997 A
D384743 Chia Oct 1997 S
5676662 Fleischhacker et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5688266 Edwards et al. Nov 1997 A
5690691 Chen et al. Nov 1997 A
5693043 Kittrell et al. Dec 1997 A
5704361 Seward et al. Jan 1998 A
5707352 Sekins et al. Jan 1998 A
5720287 Chapelon et al. Feb 1998 A
5722397 Eppstein Mar 1998 A
5722401 Pietroski et al. Mar 1998 A
5762066 Law et al. Jun 1998 A
5767692 Antonello et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5776141 Klein et al. Jul 1998 A
5779715 Tu Jul 1998 A
5782760 Schaer Jul 1998 A
5782828 Chen et al. Jul 1998 A
5782900 de la Rama et al. Jul 1998 A
5792140 Tu et al. Aug 1998 A
5792187 Adams Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800392 Racchini Sep 1998 A
5803083 Buck et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5817018 Ohtomo Oct 1998 A
5824087 Aspden et al. Oct 1998 A
5840031 Crowley Nov 1998 A
5840066 Matsuda et al. Nov 1998 A
5840076 Swanson et al. Nov 1998 A
5843020 Tu et al. Dec 1998 A
5843152 Tu et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5849028 Chen Dec 1998 A
5853368 Solomon et al. Dec 1998 A
5860974 Abele Jan 1999 A
5861021 Thome et al. Jan 1999 A
5863291 Schaer Jan 1999 A
5865787 Shapland et al. Feb 1999 A
5865801 Houser Feb 1999 A
5868708 Hart et al. Feb 1999 A
5868741 Chia et al. Feb 1999 A
5868779 Ruiz Feb 1999 A
5871449 Brown Feb 1999 A
5876340 Tu et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5882333 Schaer et al. Mar 1999 A
5891027 Tu et al. Apr 1999 A
5891135 Jackson Apr 1999 A
5891137 Chia et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5895355 Schaer Apr 1999 A
5897554 Chia et al. Apr 1999 A
5906636 Casscells, III et al. May 1999 A
5913856 Chia et al. Jun 1999 A
5916170 Kolz et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5919187 Guglielmi et al. Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5924997 Campbell Jul 1999 A
5931811 Haissaguerre Aug 1999 A
5935063 Nguyen Aug 1999 A
5935075 Casscells et al. Aug 1999 A
5938660 Swartz et al. Aug 1999 A
5941845 Tu et al. Aug 1999 A
5944710 Dev et al. Aug 1999 A
5951471 de la Rama et al. Sep 1999 A
5954649 Chia et al. Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5954719 Chen et al. Sep 1999 A
5964751 Amplatz et al. Oct 1999 A
5971968 Tu et al. Oct 1999 A
5971983 Lesh Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5980515 Tu Nov 1999 A
6002955 Willems et al. Dec 1999 A
6002956 Schaer Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6006123 Nguyen et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6011995 Guglielmi et al. Jan 2000 A
6012457 Lesh Jan 2000 A
6013053 Bower et al. Jan 2000 A
6016437 Tu et al. Jan 2000 A
6017274 Sherman et al. Jan 2000 A
6022319 Willard Feb 2000 A
6024740 Lesh Feb 2000 A
6026326 Bardy Feb 2000 A
6029091 de la Rama et al. Feb 2000 A
6033402 Tu et al. Mar 2000 A
6033403 Tu et al. Mar 2000 A
6041252 Walker et al. Mar 2000 A
6055859 Kozuka et al. May 2000 A
6056744 Edwards May 2000 A
6058328 Levine et al. May 2000 A
6059423 Knopick May 2000 A
6063077 Schaer May 2000 A
6064902 Haissaguerre May 2000 A
6066134 Eggers et al. May 2000 A
6068629 Haissaguerre et al. May 2000 A
6071279 Whayne et al. Jun 2000 A
6073052 Zelickson et al. Jun 2000 A
6080151 Swartz et al. Jun 2000 A
6083255 Laufer et al. Jul 2000 A
6094988 Aindow Aug 2000 A
6096054 Wyzgala et al. Aug 2000 A
6102908 Tu et al. Aug 2000 A
6106474 Koger et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6123456 Lyons Sep 2000 A
6128522 Acker et al. Oct 2000 A
6135999 Fanton et al. Oct 2000 A
6146379 Fleischman Nov 2000 A
6149620 Baker et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152920 Thompson Nov 2000 A
6161543 Cox et al. Dec 2000 A
6163716 Edwards Dec 2000 A
6164283 Lesh Dec 2000 A
6166092 Sekins et al. Dec 2000 A
6171306 Swanson et al. Jan 2001 B1
6183492 Hart et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6190382 Ormsby et al. Feb 2001 B1
6193713 Geistert et al. Feb 2001 B1
6196059 Kosslinger et al. Mar 2001 B1
6197023 Muntermann Mar 2001 B1
6200269 Lin et al. Mar 2001 B1
6200315 Gaiser et al. Mar 2001 B1
6200333 Laufer Mar 2001 B1
6203525 Whayne Mar 2001 B1
6203531 Ockuly et al. Mar 2001 B1
6206831 Suorsa et al. Mar 2001 B1
6208142 Wagshul Mar 2001 B1
6210356 Anderson et al. Apr 2001 B1
6212426 Swanson Apr 2001 B1
6216704 Ingle et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6221070 Tu et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6233477 Chia et al. May 2001 B1
6235025 Swartz et al. May 2001 B1
6237605 Vaska et al. May 2001 B1
6238335 Silverman et al. May 2001 B1
6238390 Tu et al. May 2001 B1
6240307 Beatty et al. May 2001 B1
6241692 Tu et al. Jun 2001 B1
6241726 Chia et al. Jun 2001 B1
6241727 Tu et al. Jun 2001 B1
6241754 Swanson et al. Jun 2001 B1
6245026 Campbell et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245067 Tu et al. Jun 2001 B1
6246899 Chia et al. Jun 2001 B1
6246912 Sluijter Jun 2001 B1
6246914 de la Rama et al. Jun 2001 B1
6251107 Schaer Jun 2001 B1
6251109 Hassett et al. Jun 2001 B1
6251130 Dobak, III et al. Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6254599 Lesh et al. Jul 2001 B1
6259941 Chia et al. Jul 2001 B1
6272377 Sweeney et al. Aug 2001 B1
6273886 Edwards et al. Aug 2001 B1
6273907 Laufer Aug 2001 B1
6278351 Wheatley Aug 2001 B1
6280402 Ishibashi et al. Aug 2001 B1
6282949 Axelsson Sep 2001 B1
6283127 Sterman et al. Sep 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287306 Kroll et al. Sep 2001 B1
6290674 Roue et al. Sep 2001 B1
6290697 Tu et al. Sep 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6299633 Laufer Oct 2001 B1
6302875 Makower et al. Oct 2001 B1
6302880 Schaer Oct 2001 B1
6305378 Lesh Oct 2001 B1
6306133 Tu et al. Oct 2001 B1
6308090 Tu et al. Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6314325 Fitz Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6321121 Zelickson et al. Nov 2001 B1
6322558 Taylor et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6328699 Eigler et al. Dec 2001 B1
6330473 Swanson et al. Dec 2001 B1
6332880 Yang et al. Dec 2001 B1
6347247 Dev et al. Feb 2002 B1
6355030 Aldrich et al. Mar 2002 B1
6355051 Sisskind et al. Mar 2002 B1
6383151 Diederich et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6400982 Sweeney et al. Jun 2002 B2
6411852 Danek et al. Jun 2002 B1
6413255 Stem Jul 2002 B1
6423026 Gesswein et al. Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6447443 Keogh et al. Sep 2002 B1
6461314 Pant et al. Oct 2002 B1
6466811 Hassett et al. Oct 2002 B1
6475146 Frelburger et al. Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6488673 Laufer et al. Dec 2002 B1
6488679 Swanson et al. Dec 2002 B1
6491710 Satake Dec 2002 B2
6492762 Pant et al. Dec 2002 B1
6500174 Maguire et al. Dec 2002 B1
6501978 Wagshul et al. Dec 2002 B2
6506189 Rittman, III et al. Jan 2003 B1
6508774 Acker et al. Jan 2003 B1
6513385 Han et al. Feb 2003 B1
6514246 Swanson et al. Feb 2003 B1
6514249 Maguire et al. Feb 2003 B1
6517536 Hooven et al. Feb 2003 B2
6517811 John et al. Feb 2003 B2
6522930 Schaer et al. Feb 2003 B1
6527769 Langberg et al. Mar 2003 B2
6536949 Hueser Mar 2003 B1
6540744 Hassett et al. Apr 2003 B2
6542251 Mueller-Rentz Apr 2003 B2
6543274 Herrmann et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6564096 Mest May 2003 B2
6589274 Stiger et al. Jul 2003 B2
6595934 Hissong et al. Jul 2003 B1
6595989 Schaer Jul 2003 B1
6599256 Acker et al. Jul 2003 B1
6599288 Maguire et al. Jul 2003 B2
6601459 Jenni et al. Aug 2003 B1
6605084 Acker et al. Aug 2003 B2
6607476 Barnhart Aug 2003 B1
6607502 Maguire et al. Aug 2003 B1
6611720 Hata et al. Aug 2003 B2
6613045 Laufer et al. Sep 2003 B1
6615071 Casscells, III et al. Sep 2003 B1
6622041 Terry, Jr. et al. Sep 2003 B2
6622731 Daniel et al. Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6626861 Hart et al. Sep 2003 B1
6626899 Houser et al. Sep 2003 B2
6634363 Danek et al. Oct 2003 B1
6635054 Fjield et al. Oct 2003 B2
6641579 Bernardi et al. Nov 2003 B1
6642515 Yamaguchi Nov 2003 B1
6645199 Jenkens et al. Nov 2003 B1
6645202 Pless et al. Nov 2003 B1
6652515 Maguire et al. Nov 2003 B1
6652547 Rabiner et al. Nov 2003 B2
6654636 Dev et al. Nov 2003 B1
6656136 Weng et al. Dec 2003 B1
6656174 Hegde et al. Dec 2003 B1
6658279 Swanson et al. Dec 2003 B2
6660013 Rabiner et al. Dec 2003 B2
6669655 Acker et al. Dec 2003 B1
6669687 Saadat Dec 2003 B1
6671533 Chen et al. Dec 2003 B2
6671556 Osorio et al. Dec 2003 B2
6672312 Acker Jan 2004 B2
6695782 Ranucci et al. Feb 2004 B2
6718208 Hill et al. Apr 2004 B2
6719694 Weng et al. Apr 2004 B2
6719755 Sliwa, Jr. et al. Apr 2004 B2
6728563 Rashidi Apr 2004 B2
6733451 Rabiner et al. May 2004 B2
6735471 Hill et al. May 2004 B2
6740082 Shadduck May 2004 B2
6740107 Loeb et al. May 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6752805 Maguire et al. Jun 2004 B2
6758830 Schaer et al. Jul 2004 B1
6763722 Fjield et al. Jul 2004 B2
6764486 Natale Jul 2004 B2
6786904 Doscher et al. Sep 2004 B2
6787974 Fjield et al. Sep 2004 B2
6799064 Hassett Sep 2004 B1
6805128 Pless et al. Oct 2004 B1
6808524 Lopath et al. Oct 2004 B2
6837886 Collins et al. Jan 2005 B2
6840936 Sliwa et al. Jan 2005 B2
6845267 Harrison et al. Jan 2005 B2
6850801 Kieval et al. Feb 2005 B2
6862479 Whitehurst et al. Mar 2005 B1
6866760 Paolini, Jr. et al. Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6885888 Rezai Apr 2005 B2
6929608 Hutchinson et al. Aug 2005 B1
6936046 Hissong et al. Aug 2005 B2
6936047 Nasab et al. Aug 2005 B2
6939309 Beatty et al. Sep 2005 B1
6939346 Kannenberg et al. Sep 2005 B2
6947785 Beatty et al. Sep 2005 B1
6960207 Vanney et al. Nov 2005 B2
6964660 Maguire et al. Nov 2005 B2
6966908 Maguire et al. Nov 2005 B2
6969388 Goldman et al. Nov 2005 B2
6976492 Ingle et al. Dec 2005 B2
6978174 Gelfand et al. Dec 2005 B2
6984232 Vanney et al. Jan 2006 B2
6990370 Beatty et al. Jan 2006 B1
6997925 Maguire et al. Feb 2006 B2
7004911 Tu et al. Feb 2006 B1
7027869 Danek et al. Apr 2006 B2
7052493 Vaska et al. May 2006 B2
7054685 Dimmer et al. May 2006 B2
7063679 Maguire et al. Jun 2006 B2
7081114 Rashidi Jul 2006 B2
7081115 Taimisto Jul 2006 B2
7082336 Ransbury et al. Jul 2006 B2
7083614 Fjield et al. Aug 2006 B2
7089063 Lesh et al. Aug 2006 B2
7104987 Biggs et al. Sep 2006 B2
7122019 Kesten et al. Oct 2006 B1
7137963 Nita et al. Nov 2006 B2
7155284 Whitehurst et al. Dec 2006 B1
7156816 Schwartz et al. Jan 2007 B2
7158832 Kieval et al. Jan 2007 B2
7162303 Levin et al. Jan 2007 B2
7189203 Lau et al. Mar 2007 B2
7189229 Lopath et al. Mar 2007 B2
7191015 Lamson et al. Mar 2007 B2
7195628 Falkenberg Mar 2007 B2
7198635 Danek et al. Apr 2007 B2
7211045 Dala-Krishna et al. May 2007 B2
7211055 Diederich et al. May 2007 B2
7217284 Houser et al. May 2007 B2
7229437 Johnson et al. Jun 2007 B2
7229469 Witzel et al. Jun 2007 B1
7263397 Hauck et al. Aug 2007 B2
7269453 Mogul Sep 2007 B2
7311701 Gifford et al. Dec 2007 B2
7326201 Fjield et al. Feb 2008 B2
7338434 Haarstad et al. Mar 2008 B1
7340307 Maguire et al. Mar 2008 B2
7347852 Hobbs et al. Mar 2008 B2
7387126 Cox et al. Jun 2008 B2
7387629 Vanney et al. Jun 2008 B2
7425212 Danek et al. Sep 2008 B1
7444183 Knudson et al. Oct 2008 B2
7503895 Rabiner et al. Mar 2009 B2
7507235 Keogh et al. Mar 2009 B2
7529582 DiLorenzo May 2009 B1
7529589 Williams et al. May 2009 B2
7540846 Harhen et al. Jun 2009 B2
7573182 Savage Aug 2009 B2
7599736 DiLorenzo Oct 2009 B2
7616997 Kieval et al. Nov 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7621902 Nita et al. Nov 2009 B2
7625371 Morris et al. Dec 2009 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7670297 Hauck et al. Mar 2010 B1
7706882 Francischelli et al. Apr 2010 B2
RE41334 Beatty et al. May 2010 E
7717948 Demarais et al. May 2010 B2
7756583 Demarais et al. Jul 2010 B2
7819826 Diederich et al. Oct 2010 B2
7819866 Bednarek Oct 2010 B2
7824341 Krishnan Nov 2010 B2
7837676 Sinelnikov et al. Nov 2010 B2
7873417 Demarais et al. Jan 2011 B2
7881809 Rashidi Feb 2011 B2
7955293 Nita et al. Jun 2011 B2
8116883 Williams et al. Feb 2012 B2
8131371 Demarals et al. Mar 2012 B2
8131372 Levin et al. Mar 2012 B2
8145317 Demarais et al. Mar 2012 B2
8150518 Levin et al. Apr 2012 B2
8150519 Demarais et al. Apr 2012 B2
8150520 Demarais et al. Apr 2012 B2
8175711 Demarais et al. May 2012 B2
8233221 Suijver et al. Jul 2012 B2
8251986 Chornenky et al. Aug 2012 B2
8287472 Ostrovsky et al. Oct 2012 B2
8347891 Demarais et al. Jan 2013 B2
8475442 Hall et al. Jul 2013 B2
8485993 Orszulak et al. Jul 2013 B2
8504147 Deem et al. Aug 2013 B2
D697036 Kay et al. Jan 2014 S
8715209 Gertner May 2014 B2
8734438 Behnke May 2014 B2
D708810 Lewis, Jr. Jul 2014 S
8808345 Clark et al. Aug 2014 B2
D712352 George et al. Sep 2014 S
D712353 George et al. Sep 2014 S
D712833 George et al. Sep 2014 S
8974445 Warnking et al. Mar 2015 B2
20010007070 Stewart et al. Jul 2001 A1
20010007940 Tu et al. Jul 2001 A1
20010044625 Hata et al. Nov 2001 A1
20020002329 Avitall Jan 2002 A1
20020002371 Acker et al. Jan 2002 A1
20020019627 Maguire et al. Feb 2002 A1
20020065512 Fjield et al. May 2002 A1
20020065541 Fredricks et al. May 2002 A1
20020068885 Harhen et al. Jun 2002 A1
20020082594 Hata et al. Jun 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020151889 Swanson et al. Oct 2002 A1
20020165532 Hill et al. Nov 2002 A1
20020165535 Lesh et al. Nov 2002 A1
20020183682 Darvish et al. Dec 2002 A1
20030013968 Fjield et al. Jan 2003 A1
20030018367 DiLorenzo Jan 2003 A1
20030036705 Hare et al. Feb 2003 A1
20030050632 Fjield et al. Mar 2003 A1
20030050637 Maguire et al. Mar 2003 A1
20030050681 Pianca et al. Mar 2003 A1
20030055422 Lesh Mar 2003 A1
20030065263 Hare et al. Apr 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030109778 Rashidi Jun 2003 A1
20030114901 Leob et al. Jun 2003 A1
20030125790 Fastovsky et al. Jul 2003 A1
20030150464 Casscells Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030181897 Thomas et al. Sep 2003 A1
20030181963 Pellegrino et al. Sep 2003 A1
20030199747 Michlitsch et al. Oct 2003 A1
20030199767 Cespedes et al. Oct 2003 A1
20030199768 Cespedes et al. Oct 2003 A1
20030199863 Swanson et al. Oct 2003 A1
20030204138 Choi Oct 2003 A1
20030216721 Diederich et al. Nov 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030216794 Becker et al. Nov 2003 A1
20030225331 Diederich et al. Dec 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20030236443 Cespedes et al. Dec 2003 A1
20030236539 Rabiner et al. Dec 2003 A1
20040010289 Biggs et al. Jan 2004 A1
20040054362 Lopath et al. Mar 2004 A1
20040064090 Keren et al. Apr 2004 A1
20040064091 Keren et al. Apr 2004 A1
20040068257 Lopath et al. Apr 2004 A1
20040082859 Schaer Apr 2004 A1
20040097996 Rabiner et al. May 2004 A1
20040101523 Reitz et al. May 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040158151 Ranucci et al. Aug 2004 A1
20040162590 Whitehurst et al. Aug 2004 A1
20040176699 Walker et al. Sep 2004 A1
20040176757 Sinelnikov et al. Sep 2004 A1
20040215186 Cornelius et al. Oct 2004 A1
20040243102 Berg et al. Dec 2004 A1
20040243206 Tadlock Dec 2004 A1
20040249416 Yun et al. Dec 2004 A1
20040260278 Anderson et al. Dec 2004 A1
20050010263 Schauerte Jan 2005 A1
20050010270 Laufer Jan 2005 A1
20050165391 Maguire et al. Jul 2005 A1
20050171575 Dev et al. Aug 2005 A1
20050187579 Danek et al. Aug 2005 A1
20050192638 Gelfand et al. Sep 2005 A1
20050209548 Dev et al. Sep 2005 A1
20050228459 Levin et al. Oct 2005 A1
20050234523 Levin et al. Oct 2005 A1
20050240170 Zhang et al. Oct 2005 A1
20050240241 Yun et al. Oct 2005 A1
20050245892 Elkins et al. Nov 2005 A1
20050256518 Rama et al. Nov 2005 A1
20050288730 Deem et al. Dec 2005 A1
20060009753 Fjield et al. Jan 2006 A1
20060025821 Gelfand et al. Feb 2006 A1
20060041277 Deem et al. Feb 2006 A1
20060058711 Harhen et al. Mar 2006 A1
20060089674 Walters et al. Apr 2006 A1
20060100514 Lopath May 2006 A1
20060100667 Machado et al. May 2006 A1
20060111754 Rezai et al. May 2006 A1
20060121610 Rubinsky et al. Jun 2006 A1
20060142801 Demarais et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060155269 Warnking Jul 2006 A1
20060155344 Rezai et al. Jul 2006 A1
20060167437 Valencia Jul 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060167499 Palti Jul 2006 A1
20060189941 Seward et al. Aug 2006 A1
20060189960 Kesten et al. Aug 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060212076 Demarais et al. Sep 2006 A1
20060212078 Demarais et al. Sep 2006 A1
20060229594 Francischelli et al. Oct 2006 A1
20060235474 Demarais Oct 2006 A1
20060241523 Sinelnikov et al. Oct 2006 A1
20060265014 Demarais et al. Nov 2006 A1
20060265015 Demarais et al. Nov 2006 A1
20060270976 Savage et al. Nov 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20060276852 Demarais et al. Dec 2006 A1
20070066972 Ormsby et al. Mar 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070135875 Demarais et al. Jun 2007 A1
20070173899 Levin et al. Jul 2007 A1
20070244479 Beatty et al. Oct 2007 A1
20070255267 Diederich et al. Nov 2007 A1
20070265609 Thapliyal et al. Nov 2007 A1
20070265610 Thapliyal et al. Nov 2007 A1
20070265687 Deem et al. Nov 2007 A1
20070282407 Clark Dec 2007 A1
20080108988 Edwards May 2008 A1
20080140150 Zhou et al. Jun 2008 A1
20080213331 Gelfand et al. Sep 2008 A1
20080255449 Warnking et al. Oct 2008 A1
20090036948 Levin et al. Feb 2009 A1
20090062697 Zhang et al. Mar 2009 A1
20090149753 Govari et al. Jun 2009 A1
20090171202 Kirkpatrick et al. Jul 2009 A1
20090216286 DiLorenzo Aug 2009 A1
20090221939 Demarais et al. Sep 2009 A1
20090228003 Sinelnikov Sep 2009 A1
20090306739 DiLorenzo Dec 2009 A1
20090312673 Thapliyal et al. Dec 2009 A1
20090312693 Thapliyal et al. Dec 2009 A1
20090312755 Thapliyal et al. Dec 2009 A1
20100016762 Thapliyal et al. Jan 2010 A1
20100049099 Thapliyal et al. Feb 2010 A1
20100057150 Demarais et al. Mar 2010 A1
20100113928 Thapliyal et al. May 2010 A1
20100113985 Thapliyal et al. May 2010 A1
20100125198 Thapliyal et al. May 2010 A1
20100130892 Warnking May 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100152582 Thapliyal et al. Jun 2010 A1
20100174282 Demarais et al. Jul 2010 A1
20100179424 Warnking et al. Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100198065 Thapliyal et al. Aug 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100222854 Demarais et al. Sep 2010 A1
20100268307 Demarais et al. Oct 2010 A1
20110079230 Danek et al. Apr 2011 A1
20110087096 Behar Apr 2011 A1
20110087097 Behar Apr 2011 A1
20110118632 Sinelnikov et al. May 2011 A1
20110137298 Nguyen et al. Jun 2011 A1
20110172527 Gertner Jul 2011 A1
20110178516 Orszulak et al. Jul 2011 A1
20110202098 Demarais et al. Aug 2011 A1
20110207758 Sobotka et al. Aug 2011 A1
20110208096 Demarais et al. Aug 2011 A1
20110237983 Nita et al. Sep 2011 A1
20110257523 Hastings et al. Oct 2011 A1
20110257563 Thapliyal et al. Oct 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110319765 Gertner et al. Dec 2011 A1
20120065493 Gertner Mar 2012 A1
20120065554 Pikus Mar 2012 A1
20120095461 Herscher et al. Apr 2012 A1
20120123243 Hastings May 2012 A1
20120123303 Sogard et al. May 2012 A1
20120143097 Pike, Jr. Jun 2012 A1
20120165667 Altmann et al. Jun 2012 A1
20120172723 Gertner Jul 2012 A1
20120232436 Warnking Sep 2012 A1
20120238918 Gertner Sep 2012 A1
20120238919 Gertner Sep 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120316439 Behar Dec 2012 A1
20130012844 Demarais et al. Jan 2013 A1
20130072928 Schaer Mar 2013 A1
20130090650 Jenson et al. Apr 2013 A1
20130103064 Arenson et al. Apr 2013 A1
20130110012 Gertner May 2013 A1
20130131668 Schaer May 2013 A1
20130138018 Gertner May 2013 A1
20130158441 Demarais et al. Jun 2013 A1
20130158442 Demarais et al. Jun 2013 A1
20130165822 Demarais et al. Jun 2013 A1
20130165924 Mathur et al. Jun 2013 A1
20130197555 Schaer Aug 2013 A1
20130204167 Sverdlik et al. Aug 2013 A1
20130211396 Sverdlik et al. Aug 2013 A1
20130211437 Sverdlik et al. Aug 2013 A1
20130218054 Sverdlik et al. Aug 2013 A1
20130274658 Steinke et al. Oct 2013 A1
20130282084 Mathur et al. Oct 2013 A1
20130304047 Grunewald et al. Nov 2013 A1
20130331739 Gertner Dec 2013 A1
20140012133 Sverdlik et al. Jan 2014 A1
20140018794 Anderson et al. Jan 2014 A1
20140025069 Willard et al. Jan 2014 A1
20140031727 Warnking Jan 2014 A1
20140039477 Sverdlik et al. Feb 2014 A1
20140046313 Pederson et al. Feb 2014 A1
20140067029 Schauer et al. Mar 2014 A1
20140074083 Horn et al. Mar 2014 A1
20140107639 Zhang et al. Apr 2014 A1
20140163540 Iyer et al. Jun 2014 A1
20140180196 Stone et al. Jun 2014 A1
20140180197 Sverdlik et al. Jun 2014 A1
20140194785 Gertner Jul 2014 A1
20140200489 Behar et al. Jul 2014 A1
20140214018 Behar et al. Jul 2014 A1
20140249524 Kocur Sep 2014 A1
20140272110 Taylor et al. Sep 2014 A1
20140275924 Min et al. Sep 2014 A1
20140276742 Nabutovsky et al. Sep 2014 A1
20140276752 Wang et al. Sep 2014 A1
20140276755 Cao et al. Sep 2014 A1
20140276789 Dandler et al. Sep 2014 A1
20140277033 Taylor et al. Sep 2014 A1
20150223877 Behar et al. Aug 2015 A1
20150290427 Warnking Oct 2015 A1
20150335919 Behar et al. Nov 2015 A1
20160016016 Taylor et al. Jan 2016 A1
Foreign Referenced Citations (73)
Number Date Country
20 2005 022 060 Nov 2012 DE
0659387 Jun 1995 EP
0 767 630 Apr 1997 EP
0 774 276 May 1997 EP
1042990 Oct 2000 EP
1 100 375 May 2001 EP
1 384 445 Jan 2004 EP
1598024 Nov 2005 EP
1 647 305 Apr 2006 EP
2 218 479 Aug 2010 EP
2 457 614 May 2012 EP
2 460 486 Jun 2012 EP
2 495 012 Sep 2012 EP
2 521 593 Nov 2012 EP
2 561 903 Feb 2013 EP
2 561 905 Feb 2013 EP
2 626 022 Aug 2013 EP
2 632 373 Sep 2013 EP
2 662 041 Nov 2013 EP
2 662 043 Nov 2013 EP
2037166 Jul 1980 GB
07-178173 Jul 1995 JP
10-127678 May 1998 JP
11-218100 Aug 1999 JP
2002-078809 Mar 2002 JP
WO 9000420 Jan 1990 WO
WO 9207622 May 1992 WO
WO 9220291 Nov 1992 WO
WO 9405365 Mar 1994 WO
WO 9411057 May 1994 WO
WO 9519143 Jul 1995 WO
WO 9525472 Sep 1995 WO
WO 9600039 Jan 1996 WO
WO 9713463 Apr 1997 WO
WO 9736548 Oct 1997 WO
WO 9841178 Sep 1998 WO
WO 9842403 Oct 1998 WO
WO 9849957 Nov 1998 WO
WO 9852465 Nov 1998 WO
WO 9902096 Jan 1999 WO
WO 9935987 Jul 1999 WO
WO 9944519 Sep 1999 WO
WO-9944523 Sep 1999 WO
WO 9944523 Sep 1999 WO
WO 9952423 Oct 1999 WO
WO 9956812 Nov 1999 WO
WO 0016850 Mar 2000 WO
WO 0027292 May 2000 WO
WO 0042934 Jul 2000 WO
WO 0051511 Sep 2000 WO
WO 0051683 Sep 2000 WO
WO 0056237 Sep 2000 WO
WO 0057495 Sep 2000 WO
WO 0067648 Nov 2000 WO
WO 0067656 Nov 2000 WO
WO 0067830 Nov 2000 WO
WO 0067832 Nov 2000 WO
WO 0113357 Feb 2001 WO
WO 0122897 Apr 2001 WO
WO 0170114 Sep 2001 WO
WO 0180723 Nov 2001 WO
WO 0182814 Nov 2001 WO
WO 0137925 Dec 2001 WO
WO 0205868 Jan 2002 WO
WO 0180723 Apr 2002 WO
WO 02083196 Oct 2002 WO
WO 02085192 Oct 2002 WO
WO 03003930 Jan 2003 WO
WO-03059437 Jul 2003 WO
WO 2004023978 Mar 2004 WO
WO-2006041881 Apr 2006 WO
WO 2012112165 Aug 2012 WO
WO-2012112165 Aug 2012 WO
Non-Patent Literature Citations (139)
Entry
Swain, et al. Gastrointestinal Endoscopy. 1994; 40:AB35.
Arruda, M. S., et al. “Development and validation of an ECG algorithm for identifying aecessory pathway ablation site in Wolff-ParkinsonWhite syndrome.” J Cardiovasc Electrophysiol, 9:2-12 (1998).
Avitall, B., et al. “The creation of linear continuous lesions in the atria with an expandable loop catheter.” J Am Coll Cardiol, 33,4:972-984 (1999).
Bartlett, T. G., et al. “Current management of the Wolff-Parkinson-White syndrome.” J Card Surg, 8:503-515 (1993).
Benito, F., et al. “Radio frequency catheter ablation of accessory pathways in infants,” Heart, 78: 160-162 (1997).
Blumenfeld, J. D., et al. “β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in norrnotensive and hypertensive subjects.” AJH, 12:451-459 (1999).
Callans, D. J. “Narrowing ofthe superior vena cava-right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: Analysis with intracardiac echocardiography.” JACC, 33:1667-1670 (1999).
Cao, H., et al. “Flow effect on lesion formation in RF cardiac catheter ablation.” IEEE T Bio-Med Eng, 48:425-433 (2001).
Chen, Shih-Ann, M.D., “Initiation of Atrial Fibrillation by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 100(18):1879-86, (1999).
Chen, S.-A., et al. “Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: An eight-year survey of 3,966 consecutive procedures in a tertiary referral center.” Am J Cardiol, 77 :41-46 (1996).
Chinitz, Larry A., “Mapping Reentry Around Atriotomy Scars Using Double Potentials,” PACE, 19:1978-1983 (1996).
Cioni, R., et al. “Renal artery stenting in patients with a solitary functioning kidney.” Cardiovasc Intervent Radiol, 24:372-377 (2001).
Cosby, R. L., et al. “The role of the sympathetic nervous system and vasopressin in the pathogenesis of the abnormal sodium and water.” Nefrologia, V, 4:271-277 (1985).
Cosio, Francisco G., “Atrial Flutter Mapping and Ablation II,” Pacing & Clin. Electrophysiol. 19(6):965-75, (1996).
Cox, J. L. “The status of surgery for cardiac arrhythmias.” Circulation, 71 :413-417 (1985).
Cox, J. L., et al. “Five-year experience with the Maze procedure for atrial fibrillation.” Ann Thorac Surg, 56:814-824 (1993).
Cruickshank, J. M. “Beta-blockers continue to surprise us.” Eur Heart J, 21:354-364 (2000).
Curtis, J. J., et al. “Surgical therapy for persistent hypertension after renal transplantation,” Transplantation, 31:125-128 (1981).
Demazumder, D., et al. “Comparison of irrigated electrode designs for radiofrequency ablation of myocardium.” J Interv Card Electr, 5:391-400 (2001).
DiBona, G. F. “Neural control of the kidney: Functionally specific renal sympathetic nerve fibers.” Am J Physiol Regulatory Integrative Comp Physiol, 279:R1517-R1524 (2000).
DiBona, G. F. “Sympathetic nervous system and kidney in hypertension,” Nephrol and Hypertension, 11: 197-200 (2002).
DiBona, G. F., et al. “Neural control of renal function,” Physiol Rev, 77:75-197 (1997).
DiBona, G. F., et al. “Renal hemodynamic effects of activation of specific renal sympathetic nerve fiber groups.” Am J Physiol Regul Integr Comp Physiol, 276:R539-R549 (1999).
Doggrell, S. A., et al. “Rat models of hypertension, cardiac hypertrophy and failure.” Cardiovasc Res, 39:89-105 (1998).
Dong, Q., et al. “Diagnosis ofrenal vascular disease with MR angiography.” RadioGraphies, 19:1535-1554 (1999).
Dubuc, M., et al. “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter,” J Interv Cardiac Electrophysiol, 2:285-292 (1998).
Feld, Gregory K., “Radiofrequency Catheter Ablation for the Treatment of Human Type I Atrial Flutter,” Circulation, 86:1233-1240 (1992).
Gallagher, John J., “Wolff-Parkinson-White Syndrome: Surgery to Radiofrequency Catheter Ablation,” PACE, 20:512-533 (1997).
Gilard, M., et al. “Angiographic anatomy ofthe coronary sinus and its tributaries.” PACE, 21:2280-2284 (1998).
Goriseh, W., et al. “Heat-indueed contraction of blood vessels.” Lasers Surg Med, 2:1-13 (1982).
Haines, D. E., et al. “Tissue heating during radiofrequeney catheter ablation; A thermodynamic model and observations in isolated perfused and superfused canine right ventrieular free wall.” PACE, 12:962-976 (1989).
Haissaguerre, Michel, “Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Venous Foci,” Circulation, 101:1409-1417 (2000).
Haissaguerre, Michel, M.D., “Predominant Origin of Atrial Panarrythmic Triggers in the Pulmonary Veins: A Distinct Electrophysiologic Entity,” PACE, 20:1065 (1997).
Haissaguerre, Michel, M.D., “Radiofrequency Catheter Ablation in Unusual Mechanisms of Atrial Fibrillation,” J Cardiovasc Electrophysiol, 5:743-751 (1994).
Haissaguerre, Michel, M.D., “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” J Cardiovasc Electrophysiol, 7:1132-1144 (1996).
Haissaguerre, Michel, M.D., “Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins,” N England J Med, 339, 10:659-666 (1998).
Han, Y-M., et al. “Renal artery embolization with diluted hot contrast medium: An experimental study,” J Vasc Interv Radiol, 12:862-868 (2001).
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin Sci, 87, 1: 13-20 (1994).
Hatala, Robert, “Radiofrequency Catheter Ablation of Left Atrial Tachycardia Originating Within the Pulmonary Vein in a Patient with Dextrocardia,” PACE, 19:999-1002 (1996).
Hindricks, G. “The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias.” Eur Heart J, 14:1644-1653 (1993).
Ho, S. Y., et al. “Architecture ofthe pulmonary veins: Relevance to radiofrequency ablation.” Heart, 86:265-270 (2001).
Hocini, Meleze, “Concealed Left Pulmonary Vein Potentials Unmasked by Left Atrial Stimulation,” PACE, 23:1832-1835 (2000).
Hocini, Meleze, “Multiple Sources Initating Atrial Fibrillation from a Single Pulmonary Vein Identified by a Circumferential Catheter,” PACE, 23:1828-1831 (2000).
Hsieh, Ming-Hsiung, M.D., “Double Multielectrode Mapping Catheters Facilitate Radiofrequency Catheter Ablation of Focal Atrial Fibrillation Originating from Pulmonary Veins,” J Cardiovasc Electrophysiol, 10:136-144 (1998).
Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats,” Hypertension 32, pp. 249-254 (1998).
Huang, S. K. S., et al. “Radiofrequency catheter ablation of cardiac arrhythmias: Basic concepts and clinical applications.” 2nd ed. Armonk, NY: Futura Publishing Co. (2000).
Jackman, W. M., et al. “Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction.” N England J Med, 327, 5:313-318 (Jul. 30, 1992).
Jain, M. K., et al. “A three-dimensional finite element model of radiofrequency ablation with blood flow and its experimental validation.” Ann Biomed Eng, 28:1075-1084 (2000).
Jais, Pierre, M.D., “A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation,” Circulation, 95(3): 572-576 (1996).
Janssen, B. J. A., et al. “Renal nerves in hypertension.” Miner Electrolyte Metab, 15:74-82 (1989).
Kapural, L., et al. “Radiofrequency ablation for chronic pain control.” Curr Pain Headache Rep, 5:517-525 (2001).
Kay, G. Neal, “Radiofrequency Ablation for Treatment of Primary Atrial Tachycardia,” JACC 21:901-909 (1993).
Koepke, J. P., et al. “The physiology teacher: Functions ofthe renal nerves.” The Physiologist, 28, 1 :47-52 (1985).
Kompanowska, E., et al. “Early effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow,” J Physiol, 53I.2:527-534 (2001).
Krimholtz et al., “New Equivalent Circuits for Elementary Piezoelectric Transducers,” Electronics Lettres, vol. 6, No. 13, pp. 398-399, Jun. 25, 1970.
Kumagai, Koichiro, “Treatment of Mixed Atrial Fibrillation and Typical Atrial Flutter by Hybrid Catheter Ablation,” PACE 23: 1839-1842 (2000).
Labonte, S. “Numerieal model for radio-frequency ablation of the endocardium and its experimental validation.” IEEE T Bio-med Eng, 41,2:108-115 (1994).
Lee, S.-J., et al. “Ultrasonic energy in endoscopic surgery,” Yonsei Med J, 40:545-549 (1999).
Leertouwer, T. c., et al. “In-vitro validation, with histology, of intravascular ultrasound in renal arteries.” J Hypertens, 17:271-277 (1999).
Lesh, M.D., “An Anatomic Approach to Prevention of Atrial Fibrillation: Pulmonary Vein Isolation with Through-the-Balloon Ultrasound Ablation (TTB-US),” Thorac. Cardiovasc. Surg. 47 (1999) (Suppl.) 347-51.
Lesh, Michael D., M.D., “Radiofrequency Catheter Ablation of Atrial Arrhythmias,” 1994.
Liem, L. Bing, “In Vitro and In Vivo Results of Transcatheter Microwave Ablation Using Forward-Firing Tip Antenna Design,” 1996.
Lin, Wei-Shiang, M.D., “Pulmonary Vein Morphology in Patients with Paroxysmal Atrial Fibrillation Initiated by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 101(11):1274-81, 2000.
Lowe, J. E. “Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias.” J Card Surg, 1 :117-134 (1986).
Lundin, S. et al. “Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods.” Acta Physiol Scand, 120,2:265-272 (1984).
Lustgarten, D. L., et al. “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias,” Progr Cardiovasc Dis, 41:481-498 (1999).
Mallavarapu, Christopher, “Radiofrequency Catheter Ablation of Atrial Tachycardia with Unusual Left Atrial Sites of Origin,” 1996.
McRury, I. D., et al. “Nonunifonn heating during radiofrequency catheter ablation with long electrodes.” Circulation, 96:4057-4064 (1997).
Mehdirad, A., et al. “Temperature controlled RF ablation in canine ventricle and coronary sinus using 7 Fr or 5 Fr ablation electrodes.” PACE, 21:310-321 (1998).
Miller, B. F., and Keane, C. B. “Miller-Keane Encyclopedia & Dictionary 0/ Medicine, Nursing, & Allied Health.” Philadelphia: Saunders (1997) (“ablation”).
Misaki, T., et al. “Surgical treatment ofpatients with Wolff-ParkinsonWhite syndrome and associated Ebstein's anomaly.” J Thorae Cardiovase Surg, 110: 1702-1707 (1995).
Moak, J. P., et al. “Case report: Pulmonary vein stenosis following RF ablation of paroxysmal atrial fibrillation: Successful treatment with balloon dilation.” J Interv Card Electrophys, 4:621-631 (2000).
Montenero, Sandro, Annibale, “Electrograms for Identification of the Atrial Ablation Site During Catheter Ablation of Accessory Pathways,” 1996.
Morrissey, D. M., “Sympathectomy in the treatment of hypertension.” Lancet, CCLXIV:403-408 (1953).
Moubarak, Jean B., “Pulmonary Veins-Left Atrial Junction: Anatomic and Histological Study,” Pacing & Clin. Electrophys. 23(11 pt. 2):1836-8, 2000.
Nakagawa, H., et al. “Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequeney ablation with a saline-irrigated electrode versus temperature control in a eanine thigh muscle preparation.” Circulation, 91 :2264-2273 (1995).
Nakagawa, H., et al. “Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling.” Circulation, 98:458-465 (1998).
Nakagawa, A., et al. “Selective ablation of porcine and rabbit liver tissue using radiofrequency: Preclinical study.” Eur Surg Res, 31: 3 71-379 (1999).
Neutel, J. M. “Hypertension and its management: A problem in need of new treatment strategies.” JRAAS, I:S 1 O-S 13 (2000).
Nozawa, T., et al. “Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats.” Heart Vessels, 16:51-56 (2002).
O'Connor, B. K., et al. “Radiofrequeney ablation of a posteroseptal accessory pathway via the middle cardiac vein in a six-year-old child.” PACE, 20:2504-2507 (1997).
Oliveira et al., “Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats,” Hypertension Suppl. II vol. 19 No. 2, pp. 17-21 (1992).
Oral, H., et al. “Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.” Circulation, 105:1 077-1081 (2002).
Page, I., et al. “The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension.” J Clin Invest, XIV:27-30 (1935).
Panescu, D., et al. “Radiofrequency multielectrode catheter ablation in the atrium.” Phys Med Biol, 44:899-915 (1999).
Pavin, D., et al. “Permanent left atrial tachyeardia: Radiofrequency catheter ablation through the eoronary sinus.” J Cardiovasc Electrophysiol, 12:395-398 (2002).
Peet, M., “Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy,” Am. J. Surgery, pp. 48-68 (1948).
Petersen, H. H., et al. “Lesion dimensions during temperature controlled radiofrequency catheter ablation of left ventricular porcine myocardium: Impact of ablation site, electrode size, and convective cooling.” Circulation, 99:319-325 (1999).
Pohl, M.A. “Renovaseular hypertension and isehemie nephropathy” A chapter in a book edited by Sehrier, R. W. “Atlas 0f diseases of the kidney: Hypertension and the kidney.” Blackwell Science (1999).
Prager, Nelson, A., “Long Term Effectiveness of Surgical Treatment of Ectopic Atrial Tachycardia,” 1993.
Pugsley, M. K., et al. “The vascular system: An overview of structure and function.” J Pharmacol Toxical Methods, 44:333-340 (2000).
Rappaport et al., “Wide-Aperture Microwave Catheter-Based Cardiac Ablation”, Proceedings of the First Joint BMES/EMBS Conference, Oct. 13-16, 1999, p. 314.
Reuter, David, M.D., “Future Directions of Electrotherapy for Atrial Fibrillation,” 1997.
Robbins, Ivan, M.D., “Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation,” Circulation, 98:1769-1775 (1998).
Sanderson, J. E., et al. “Effect of B-blockage on baroreceptor and autonomic function in heart failure.” Clin Sei, 69:137-146 (1999).
Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation,” Circulation, 102:2774-2780 (2000).
Scheinman, Melvin M., “NASPE Survey on Catheter Ablation,” 1995.
Scheinman, M. M., et al. “The 1998 NASPE prospective catheter ablation registry.” PACE, 23:1020-1028 (2000).
Smithwick et al., “Splanchnicectomy for Essential Hypertension,” J. Am. Med. Assn. 152:16, pp. 1501-1504 (1953).
Solis-Herruzo et al., “Effects of Lumbar Sympathetic Block on Kidney Function in Cirrhotic Patients with Hepatorenal Syndrome,” J. Hepatol. 5, pp. 167-173 (1987).
Stella, A., et al. “Effects of reversible renal denervation on haemodynamic and excretory functions of the ipsilateral and contralateral kidney in the cat,” J Hypertension, 4: 181-188 (1986).
Stellbrink, C., et al. “Transcoronary venous radiofrequency catheter ablation ofventricular tachyeardia.” J Cardiovasc Electrophysiol, 8:916-921 (1997).
Swartz, John F., “A Catheter-based Curative Approach to Atrial Fibrillation in Humans,” 1994.
Swartz, John F., M.D., “Radiofrequency Endocardial Catheter Ablation of Accessory Atrioventricular Pathway Atrial Insertion Sites,” Circulation, 87:487-499 1993.
Takahashi, H., et al. “Retardation of the development of hypertension in DOCA-salt rats by renal denervation.” Jpn Circ J, 48:567-574 (1984).
Tanaka et al., “A new radiofrequency thermal balloon catheter for pulmonary vein isolation,” Journal of the American College of Cardiology 38(7): 2079-86, Dec. 2001.
Tracy, Cynthia M., “Radiofrequency Catheter Ablation of Ectopic Atrial Tachycardia Using Paced Activation Sequence Mapping,” J. of the Amer. College of Cardiol. 21(4):910-7, 1993.
Tungjitkusolmun, S. “Ablation.” A chapter in a book edited by Webster, J. G., “Minimally invasive medical technology.” Bristol UK: IOP Publishing, 219 (2001).
Uchida, F., et al. “Effect of radio frequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites,” PACE, 21:2517-2521 (1998).
Uflacker, R., “Atlas of vascular anatomy: An angiographic approach.” Baltimore: Williams & Wilkins, 424 (1997).
Valente, J. F. “Laparoscopic renal denervation for intractable ADPKD-related pain,” Nephrol Dial Transplant, 16:160 (2001).
Van Hare, G. F., et al. “Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children.” JACC, 17:1613-1620 (1991).
Van Hare, George F., “Radiofrequency Catheter Ablation of Supraventricular Arrhythmias in Patients With Congenital Heart Disease: Results and Technical Considerations,” J. of the Amer. College of Cardiol. 22(3):883-90, 1993.
Volkmer, Marius, M.D., “Focal Atrial Tachycardia from Deep Inside the Pulmonary Veins,” 1997.
Vujaskovie, Z., et al. “Effects of intraoperative hyperthermia on canine seiatie nerve: Histopathologie and morphometric studies.” Int J Hyperthermia, 10,6:845-855 (1994).
Walsh, Edward P., M.D., “Transcatheter Ablation of Ectopic Atrial Tachycardia in Young Patients Using Radiofrequency Current,” 1992.
Weinstock, M., et al. “Renal denervation prevents sodium retention and hypertension in salt-sensitive rabbits with genetic baroreflex impairment,” Clinical Science, 90:287-293 (1996).
Weir, M. R., et al. “The renin-angiotensin-aldosterone system: A specific target for hypertension management.” Am J Hypertens,12:205S-213S (1999).
Yamamoto, T., et al. “Blood velocity profiles in the human renal artery by Doppler ultrasound and their relationship to atherosclerosis.” Arterioscl Throm Vas, 16: 172-177 (1996).
Zhang et al., “The development of a RF electrical pole catheter for heart ablation,” China Academic Journal Electronic Publishing House 23(5): 279-80, Sep. 1999.
Zipes, Douglas P., M.D., “Catheter Ablation of Arrhythmias,” 1994.
Reexam Appl. 95/002,110, Filed: Aug. 29, 2012, Demarais et al.
Reexam Appl. 95/002,209, Filed: Sep. 14, 2012, Levin et al.
Reexam Appl. 95/002,233, Filed: Sep. 13, 2012, Levin et al.
Reexam Appl. 95/002,243, Filed: Sep. 13, 2012, Levin et al.
Reexam Appl. 95/002,253, Filed: Sep. 13, 2012, Demarais et al.
Reexam Appl. 95/002,255, Filed: Sep. 13, 2012, Demarais et al.
Reexam Appl. 95/002,292, Filed: Sep. 14, 2012, Demarais et al.
Reexam Appl. 95/002,327, Filed: Sep. 14, 2012, Demarais et al.
Reexam Appl. 95/002,335, Filed: Sep. 14, 2012, Demarais et al.
Reexam Appl. 95/002,336, Filed: Sep. 14, 2012, Levin et al.
Reexam Appl. 95/002,356, Filed: Sep. 14, 2012, Demarais et al.
Diederich C.J et al. Transurethral ultrasound array for prostate thermal therapy: initial studies, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control IEEE USA, vol. 43, No. 6 Nov. 1996 pp. 1011-1022.
Campese, et al., Renal afferent denervation prevents hypertension in rats with chronic renal failure, Hypertension, 25:878-882 (1995).
Dibona, Renal nerves in compensatory renal response to contralateral renal denervation, Renal Physiology, 238 (1):F26-F30 (1980).
Diederich C.J. et al. “Transurethral Ultrasound Array for Prostate Thermal Therapy: Initial Studies”, IEEE Transactions on Ultrasonic, Ferroelectronics And Frequency Control IEEEE USA, vol. 43No. 6 Nov. 1996 pp. 1011-1022.
Oliveira, et a., Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats, Hypertension 19:17-21 (1992).
Smithwick, R.H., Surgery in hypertension, Lancet, 2:65 (1948).
Smithwick, R.H., Surgical treatment of hypertension, Am J Med 4:744-759 (1948).
Related Publications (1)
Number Date Country
20130072928 A1 Mar 2013 US
Provisional Applications (2)
Number Date Country
60419317 Oct 2002 US
60393339 Jul 2002 US
Continuations (1)
Number Date Country
Parent 10611838 Jun 2003 US
Child 13478825 US